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ABSTRACT 
 
Autism spectrum disorders (ASD) and intellectual disability (ID) are the two most 
frequently reported, often co-morbid, neurodevelopmental disorders that affect 
children all over the world. Previously, a genetic association of the ZBTB20 gene, 
located at chromosome 3q13.2, with ASD and ID was identified. The gene is 
highly expressed in developing brain and encodes two isoforms of 668- (short 
isoform) and 741- (long isoform) amino acid proteins that belong to the BTB 
(broad complex, tramtrack, bric-a-brac) – zinc finger family of transcription 
factors. 
 
The human ZBTB20 protein was functionally characterized using various 
molecular and cellular approaches, to elucidate its contribution to ASD and ID. 
ZBTB20 is primarily localized in the nucleus, the short and long isoforms of 
ZBTB20 form homodimers and heterodimers. The N-terminal region of ZBTB20 
that includes the BTB domain appears to be critical for dimerization. A ZBTB20 
yeast two-hybrid screen was performed using human fetal brain cDNA library, to 
determine its function in neuronal cells. Several brain-expressed proteins that 
interact with ZBTB20, including the E2 SUMO conjugating enzyme UBC9 were 
identified. Moreover, ZBTB20 contains two putative conserved SUMOylation 
(ΨKXE) motifs. The ZBTB20 protein undergoes SUMOylation, binds SUMO1, 
and the N-terminal region of ZBTB20 is critical for its interaction with UBC9. The 
!
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ZBTB20 K330 residue in SUMOylation motif 1 is the likely target for in vivo 
SUMOylation. Altering residue K330 had no effect on ZBTB20 subcellular 
localization, stability or repression activity, but interfered with its dimerization.  
 
Consistent with studies in mice, ZBTB20 functions as a transcriptional repressor. 
Overexpression of wild type ZBTB20, but not the ASD/ID-associated ZBTB20 
mutants in HEK293H cells resulted in significantly reduced expression of 
transcription factor genes MEF2C, TBR1 and FEZF2, previously shown to be 
associated with ASD and ID. These results suggest a potential contribution of a 
ZBTB20-dependent transcription regulation mechanism in neurodevelopmental 
disorders such as ASD and ID. 
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PREFACE 
 
The goal of this study is to functionally characterize the BTB (Broad complex, 
Tramtrack, Bric-a-Brac)-zinc finger protein, ZBTB20, and understand its role in 
the development of autism spectrum disorder (ASD) and intellectual disability 
(ID).  
 
The first chapter provides a detailed literature review of the human ZBTB20. To 
understand the physiological functions of human ZBTB20, the known functions of 
murine Zbtb20 protein are described. The ZBTB20 gene defects in 
neurodevelopmental disorders including autism spectrum disorder and 
intellectual disability are reviewed. Finally, the post-translational modification 
SUMOylation and the biological functions regulated by it are explained.  
 
The second chapter describes the intracellular localization of human ZBTB20 
protein. The homotypic and heterotypic interaction of human ZBTB20 protein was 
determined. This study also identified eight novel ZBTB20 interacting proteins in 
the human fetal brain cDNA library using the yeast two-hybrid screen.  
 
The third chapter describes the interaction of ZBTB20 with one of the ZBTB20 
interacting proteins identified in the yeast two-hybrid screen, the E2 SUMO 
conjugating enzyme UBC9. Two putative SUMOylation sites were identified in 
!
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the human ZBTB20 protein. Further, SUMOylation of ZBTB20 and its effects on 
the function of ZBTB20 were studied.  
 
The fourth chapter describes the ZBTB20-dependent transcription regulation of 
neuronal transcription factor genes, which are negatively correlated in the 
ZBTB20 coexpressed gene list. We also examined the effect of ZBTB20 long or 
short isoform overexpression on the expression of ASD and ID associated 
transcription factor genes in HEK293H cells.  
 
The fifth chapter describes the siRNA-mediated knockdown of human ZBTB20 in 
two human cell lines, human embryonic kidney HEK293H cells and the human 
neuronal progenitor ReNcell VM cells. Finally, using ZBTB20 overexpression as 
well as ZBTB20 knockdown in mammalian cells, the role of ZBTB20-dependent 
transcription regulation in ASD and ID can be determined. 
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CHAPTER 1 
 
LITERATURE REVIEW 
 
Introduction 
 
Zinc finger and BTB domain containing 20 (ZBTB20)  
 
The human ZBTB20 gene is located on chromosome 3, at position 3q13.2. The 
gene spans approximately 880 kb of genomic DNA and has 10 exons (Figure 
1.1). The ZBTB20 gene was previously known as ZNF288 (Harboe et al., 2000), 
DPZF (Zhang et al., 2001) and HOF (Mitchelmore et al., 2002).  
 
The human ZBTB20 gene was first localized to chromosome 3q13.2 using 
radiation hybrid mapping and fluorescence in situ hybridization (FISH) (Harboe et 
al., 2000). It was also identified in the human dendritic cell cDNA library (Zhang 
et al., 2001). The ZBTB20 gene encodes a protein containing the BTB/POZ 
(Broad Complex, Tramtrack, Bric a Brac/ Poxvirus and zinc finger) domain at the 
N-terminal and the C2H2 Kruppel type zinc fingers at the C-terminal domain. The 
gene encodes two protein isoforms by alternative splicing, a long isoform (741 
amino acids) and a short isoform (668 amino acids) (Figure 1.1).  
!
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Figure 1.1: Schematic diagram showing the location of the ZBTB20 gene on 
chromosome 3q13.2, ZBTB20 transcripts and protein isoforms 
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Figure 1.1: Schematic diagram showing the location of the ZBTB20 gene on 
chromosome 3q13.2, ZBTB20 transcripts and protein isoforms 
A. Ideogram of chromosome 3 showing the location of the ZBTB20 gene at 
chromosomal position 3q13.2. The ZBTB20 gene forms two major transcripts, ZBTB20 
short isoform transcript (NM_015642) and ZBTB20 long isoform transcript 
(NM_001164342). The short isoform transcript has exons 1-10; green shaded region 
indicates the short isoform translated region; arrow indicates the translation initiation in 
the ZBTB20 short isoform transcript. The long isoform transcript has exons 7A, 7B, 8, 9 
and 10; brown shaded region indicates the long isoform translated region; arrow 
indicates the translation initiation in the ZBTB20 long isoform transcript. B. Schematic 
representation of both the ZBTB20 short (668 amino acids) and long (741 amino acids) 
isoform proteins. The BTB domain (BTB) and the C2H2 Kruppel type zinc fingers (ZnF) 
are shown. A region specific to the long isoform (1-73 amino acids) is indicated in 
orange.   
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The ZBTB20 protein was extensively studied in the mouse model system. The 
murine Zbtb20 gene was first isolated from mouse oligodendrocyte cDNA library 
and designated HOFL and HOFs, for the long and short isoforms respectively 
(Mitchelmore et al., 2002). This study demonstrated that both the isoforms of 
Zbtb20 were highly expressed in hippocampal neurons, cerebellar granule cells, 
as well as in differentiated and undifferentiated glial cells in the mouse brain. 
 
ZBTB20 belongs to the POK family of transcription factors  
 
ZBTB20 protein belongs to the BTB/POZ and Kruppel type zinc finger family 
(POK) of transcription factors. Members of the POK family play critical roles in 
various biological processes including differentiation, oncogenesis and 
development (Kelly and Daniel, 2006; Lee and Maeda, 2012). 
ZBTB20 has a unique N-terminal BTB domain that was first identified as a 
conserved sequence in the Drosophila proteins Broad complex, Tramtrack and 
Bric-a-Brac (Albagli et al., 1995). It was also identified in a group of poxvirus 
proteins and was therefore also named the Poxvirus and Zinc finger domain 
(Bardwell and Treisman, 1994). The BTB domain is a highly conserved domain 
of approximately 100 amino acids. The BTB domain of the human ZBTB20 
protein is 106 amino acids in length (Zhang et al., 2001).  
 
!
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Towards the C-terminal domain, ZBTB20 has five C2H2 Kruppel type zinc finger 
domains. The C2H2 Kruppel type zinc finger domain is one of the most common 
types of DNA-binding domains, approximately 25- to 30- amino acids in length. 
More than 600 human genes encode the tandemly repeated C2H2 zinc finger 
protein family (Collins, 1998; Kelly and Daniel, 2006), characterized by the 
consensus sequence CX2-4CX3FX5LX2HX3-4 (where X represents any amino 
acid) (Zhang et al., 2001). The conserved cysteine (C) and histidine residues (H) 
in the C2H2 zinc fingers tetrahedrally bind the Zn2+ ion, which helps in attaching 
the zinc fingers to the target DNA sequence.   
 
Both the BTB/POZ domain and the C2H2 Kruppel type Zinc finger domain are 
conserved protein domains. The BTB domain is a protein-protein interaction 
motif, which has been shown to mediate both homotypic as well as heterotypic 
interactions. PLZF (Promyelocytic Leukemia Zinc Finger) and BCL-6 (B-cell 
lymphoma-6), which belong to the POK family of transcription factors form 
homodimers via their BTB domains (Ahmad et al., 1998; Hoatlin et al., 1999; Li et 
al., 1999). The BTB domain was also shown to be involved in heterotypic 
interactions (Daniel and Reynolds, 1999; Davies et al., 1999; Okabe et al., 1998) 
as well as interaction with other non-BTB containing proteins (Geyer et al., 2003; 
Krek, 2003). The BTB domain containing proteins were identified as substrate 
specific adaptors for Cullin 3 (Cul3), a RING type E3 ubiquitin ligase (Geyer et 
!
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al., 2003; Krek, 2003) using the yeast two-hybrid screen (Xu et al., 2003) and 
mass-spectrometric analysis (Pintard et al., 2003).  
 
The BTB/POZ domain interacts with co-repressors. Some BTB domain 
containing transcription factors such as PLZF, BCL-6 etc. interact with 
components of the histone deacetylase (HDAC) complex (Dhordain et al., 1997; 
Huynh and Bardwell, 1998). The HDACs mediate removal of the acetyl group 
from histone lysine tails, causing closed chromatin conformation, leading to 
transcriptional repression. However, other BTB containing transcription factors, 
like Hypermethylated in cancer 1, HIC-1, repress transcription in an HDAC-
independent manner (Deltour et al., 2002). Thus, understanding the functional 
roles of the BTB/POZ and C2H2 Kruppel type zinc fingers in ZBTB20 could 
elucidate its possible physiological roles in neuronal development and other 
biological processes. 
 
 
The physiological roles of mouse Zbtb20 
 
Various functions have been assigned to the mouse Zbtb20 protein (Figure 1.2). 
The Zbtb20 knockout mouse model as well as the targeted deletion of the Zbtb20 
gene in specific tissues in mice has provided insight into the functioning of the 
Zbtb20 protein. Moreover, Zbtb20 overexpression studies done in mice 
!
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complemented the functions identified by Zbtb20 knockdown in cell lines or 
Zbtb20 knockout mouse models as described in the sections below. 
 
 
 
 
Figure 1.2: Schematic diagram of the known functional roles of the mouse 
Zbtb20 protein 
 
Role of mouse Zbtb20 in postnatal survival  
 
To determine the in vivo function of the Zbtb20 protein, knockout mice were 
generated (Sutherland et al., 2009). The Zbtb20 knockout mice showed growth 
retardation as well as reduced body weight and axial growth. These mice also 
showed postnatal lethality; none of these mice survived more than 12 weeks of 
age. The Zbtb20 knockout mice showed abnormal glucose homeostasis, 
hypoglycemia and metabolic dysfunction. These mice had reduced energy 
stores, especially glycogen, along with adipose tissue defects, although they did 
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not display any feeding defects (Sutherland et al., 2009). One of the unique 
phenotypes of the Zbtb20 knockout mice was liver dysfunction. Further, 
transcript-profiling analysis was performed in the liver of Zbtb20 knockout mice to 
identify the pathways involved. Growth, glucose metabolism and detoxification 
were some of the pathways affected in Zbtb20 knockout mice.  
 
Role of mouse Zbtb20 in glucose homeostasis 
 
 Zbtb20 knockout mice displayed abnormal glucose homeostasis. Fructose-1,6-
bisphosphosphatase (Fbp1) is a gluconeogenic enzyme involved in insulin 
secretion and glucose metabolism in mouse β-cells. Previous studies (Kebede et 
al., 2008; Zhang et al., 2010) showed that Fbp1 regulates glucose-stimulated 
insulin secretion in β-cells. Since Zbtb20 is highly expressed in the wild type 
pancreatic islets, Zhang and coworkers (Zhang et al., 2012) generated β-cells 
specific Zbtb20 knockout mice. They showed that Zbtb20 regulates glucose-
stimulated insulin secretion by directly binding the Fbp1 promoter and repressing 
Fbp1 gene expression. Thus Fbp1 gene expression was found to be upregulated 
when Zbtb20 protein expression was ablated. They further showed that the 
reduced expression of the Zbtb20 gene in β-cells resulted in decreased glucose 
utilization, reduced insulin secretion and impaired glucose-stimulated insulin 
secretion. Thus Zbtb20 plays a vital role in glucose homeostasis by regulating 
the transcription of the Fbp1 gene. 
!
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Role of mouse Zbtb20 in toll-like receptor triggered innate immunity  
 
As previously mentioned, ZBTB20 is highly expressed in human dendritic cells 
(Zhang et al., 2001). Besides dendritic cells, ZBTB20 is also abundantly 
expressed in immune cells including myeloid cells, macrophages, monocytes, B 
cells and T cells (Zhang et al., 2001). To study the role of Zbtb20 in immune 
cells, myeloid cell-specific Zbtb20 knockout mice were generated (Liu et al., 
2013). Interestingly, these mice were found to be resistant to endotoxin shock. 
The myeloid cell-specific Zbtb20 knockdown mice showed reduced levels of toll-
like receptor (TLR) triggered inflammatory responses, determined by challenging 
the mice with various TLR ligands and bacterial infections. Thus these mice 
showed impaired cytokine production in TLR-triggered Zbtb20 deficient myeloid 
cells.  
 
Liu and coworkers (2013) demonstrated that the murine Zbtb20 protein 
represses the inhibitory gene IκBα by binding directly to IκBα gene promoter.  
This led to reduced IκBα gene transcription as well as IκBα protein production. 
IκBα protein has been shown to impair the activity of NF-κB protein. As the 
murine Zbtb20 transcription factor represses IκBα protein, it results in NF-κB 
activation. It was found that enhanced NF-κB activation, led to increased TLR-
triggered cytokine production. Thus by selectively repressing IκBα gene, murine 
!
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Zbtb20 causes NF-κB activation which results in increased toll-like receptor-
triggered innate immune response.  
 
Role of mouse Zbtb20 as a transcriptional repressor 
 
Mouse studies involving targeted knockout of the Zbtb20 gene in various cell 
types have shown that the murine Zbtb20 protein functions as a transcriptional 
repressor. Zbtb20 knockout experiments using a Cre/loxP recombination 
approach was performed in liver (Xie et al., 2008), β-cells of the pancreas (Zhang 
et al., 2012) and myeloid cells (Liu et al., 2013) associated with innate immune 
response in mice. These Zbtb20 knockout experiments have led to the 
identification of the Zbtb20-regulated target genes. The promoter regions directly 
bound to the Zbtb20 transcription factor were identified using chromatin 
immunoprecipitation (ChIP) analysis followed by sequencing and electrophoretic 
mobility shift assays (EMSA). Ablation of murine Zbtb20 specifically in the liver 
resulted in the de-repression of alpha-fetoprotein (Afp) gene transcription. Using 
ChIP and EMSA, Xie and coworkers (2008) showed that Zbtb20 directly binds 
the -108/-53 region of the Afp gene promoter region. This was the first evidence 
supporting the role of Zbtb20 as a transcriptional repressor. 
 
As previously discussed, Zbtb20 was knocked-out in the β-cells using Cre/loxP 
technology or knocked-down in MIN6 (pancreatic β-cell line), using mouse 
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Zbtb20 gene specific siRNAs. Reduced expression of Zbtb20 resulted in 
increased Fbp-1 gene expression accompanied by hyperglycemia and impaired 
glucose-stimulated insulin secretion. Using ChIP assays in mouse pancreatic 
islets as well as in MIN6 cells, Zbtb20 was shown to directly bind the Fbp1 
promoter approximately 1 kb upstream of the transcriptional start site (Zhang et 
al., 2012).  
 
Another example of the role of Zbtb20 as a transcriptional repressor came from 
myeloid cell-specific Zbtb20 knockout mice, generated using the Cre/loxP 
approach (Liu et al., 2013). Using ChIP analysis accompanied by high throughput 
DNA sequencing (ChIP-Seq) in toll-like receptor-triggered as well as untreated 
macrophages, Liu and coworkers (2013) demonstrated that Zbtb20 directly 
bound to the IκBα gene promoter and reduced its expression. Disruption of the 
murine Zbtb20 gene and ablation of its expression showed, the Zbtb20 
transcription factor to act as a transcriptional repressor.  
 
Role of mouse Zbtb20 in hippocampal development 
 
Murine Zbtb20 protein was shown to play a significant role in hippocampal 
neurogenesis. The hippocampus is part of the limbic system involved in learning, 
memory and behavior. It is located within the temporal lobes of the brain, at the 
medial-temporal edge of the neocortex. Hippocampus formation refers to the 
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hippocampus proper (which consists of CA1, CA2, CA3 and CA4 fields, also 
called as the Cornu Ammonis), dentate gyrus and the subiculum.  
 
The murine Zbtb20 gene expression specifically coincides with early 
differentiating hippocampal CA1 and CA3 pyramidal neurons and granule cells of 
the dentate gyrus (Mitchelmore et al., 2002). Murine Zbtb20 is expressed in 
hippocampal primordium as early as mouse embryonic day, E12.5 and is later 
expressed specifically in the developing hippocampal progenitor cells and 
postmitotic neurons. This was determined by in situ hybridization using anti-
Zbtb20 antibody in the developing mouse hippocampus (Xie et al., 2010). 
 
Effect of mouse Zbtb20 knockout on hippocampal neurogenesis and 
memory in mice 
 
To determine the physiological role of Zbtb20 in hippocampal development, the 
hippocampus of Zbtb20 knockout mice were analyzed (Xie et al., 2010). These 
mice showed severe morphological defects in CA1, CA3 and dentate gyrus 
regions of the hippocampus. Xie and coworkers (2010) showed that Zbtb20 
knockout mice resulted in a reduction in size of the hippocampus. They also 
showed that the smaller hippocampus in the Zbtb20 knockout mice, as compared 
to the wild type mice, was due to increased apoptosis of hippocampal neurons.  
!
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Besides cytoarchitectural changes observed in the Zbtb20 knockout mice, Xie 
and coworkers (2010) demonstrated differential gene expression in the 
hippocampus of Zbtb20 knockout mice as compared to the wild type mice. They 
showed that expression of the neocortical layer-specific genes was markedly 
increased, while expression of hippocampal-specific genes was reduced, in the 
hippocampal CA1 field of Zbtb20 knockout mice. Thus the targeted deletion of 
Zbtb20 led to the transformation of the CA1 field to a neocortex-like structure.  
These studies done by the Zhang laboratory (Xie et al., 2010) demonstrated that 
murine Zbtb20 is involved in the specification of hippocampal CA1 pyramidal 
neuron identity.  
 
Since the hippocampus is associated with learning and memory, the effect of 
Zbtb20 knockout on hippocampus-dependent memory formation was also 
analyzed. CA1 specific Zbtb20 knockout mice were generated with the Zbtb20 
knockout restricted to the mature CA1 pyramidal cells of the hippocampus (Ren 
et al., 2012). Using various behavioral tests, Ren and coworkers demonstrated 
that these CA1-Zbtb20 knockout mice had impaired retention of spatial memory 
and reduced long-term potentiation (LTP). Thus the targeted deletion of Zbtb20 
in mice resulted in impaired hippocampal neurogenesis and memory formation. 
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Ectopic expression of murine Zbtb20 gene results in hippocampus-like 
corticoneurogenesis  
 
To study the role of Zbtb20 in hippocampal development, both long and short 
isoforms of the Zbtb20 gene were ectopically expressed in non-hippocampal 
immature pyramidal neurons (Nielsen et al., 2007). Zbtb20 was specifically 
overexpressed in the subiculum, retrosplenial and the cortical regions. This 
resulted in hippocampus-like corticoneurogenesis (Nielsen et al., 2007) and 
pyramidal cell layers expressing markers of CA1 projection neurons (Nielsen et 
al., 2010). In order to determine the behavioral defects associated with Zbtb20 
transgenic mice, Nielsen and coworkers (Nielsen et al., 2007) performed 
behavioral tests like visual cliff tests (Fox, 1965) and platform maize tests (Pompl 
et al., 1999) to measure visual and spatial memory. These studies showed that 
the Zbtb20 overexpressed mice had impaired spatial and visual memory cues as 
compared to wild type mice. These findings suggested Zbtb20 overexpression is 
associated with hippocampus-like pyramidal neuron morphogenesis and 
behavioral abnormalities associated with memory impairments.  
 
 
 
 
 
!
17 
ZBTB20 gene defects in neurodevelopmental disorders 
 
In order to identify potential candidate genes for neurodevelopmental disorders 
like autism spectrum disorders (ASD) and intellectual disability (ID), Srivastava 
and coworkers (Rimsky et al., manuscript in preparation) characterized a 
translocation breakpoint in a 10-year-old female patient with developmental delay 
and mild autism. The patient had a de novo translocation t(3;12)(q13.2;p11.2) 
which resulted in the physical disruption of the ZBTB20 gene at the 3q breakpoint 
and the SRY (sex determining region Y)-box5 gene, SOX5 at the 12p breakpoint. 
One chromosomal copy of the ZBTB20 gene was disrupted at its 5’UTR, 
identified in the patient’s lymphoblasts using appropriate FISH probes. Moreover, 
the ZBTB20 disruption resulted in significantly reduced expression of both the 
ZBTB20 gene and protein as compared to the two control individuals tested 
(Rimsky et al., manuscript in preparation). Haploinsufficiency of the ZBTB20 
gene could be one of the causative factors, responsible for the phenotype in the 
patient with the t(3;12) translocation. 
 
Additional ZBTB20 gene variants were identified in a cohort of unrelated patients 
with ASD and/or ID. Two missense ZBTB20 gene variants c.137C>G, p.P46R 
and c.1037G>T, p.G346V, shown in Figure 1.3, were identified in two unrelated 
families by Rimsky and coworkers (Koul et al., 2013; Rimsky et al., manuscript in 
preparation) but found to be absent in a significantly large number of control 
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individuals. The ZBTB20 p.P46R variant  was identified in one male patient and 
his twin sister, both affected with pervasive developmental disorders (PDD). The 
missense ZBTB20 mutation p.G346V was identified in an African American 
female patient with ASD, severe ID and no verbal abilities. Functional studies 
were performed by overexpressing both the ZBTB20 gene variants in cultured 
cortical pyramidal neurons, followed by in-depth analysis of the dendritic spine 
morphology and arborization. Ectopic expression of the ZBTB20 p.P46R variant 
resulted in abnormal spine enlargement while overexpression of the ZBTB20 
p.G346V variant caused increased basal dendritic arborization in the cultured 
cortical neurons. Thus, both ZBTB20 variants, P46R in the long isoform and 
G346V in the short isoform, are potentially associated with ASD and/or ID and 
appear to play a role in dendritic spine morphology as well as dendritic 
arborization (Koul et al., 2013; Rimsky et al., manuscript in preparation).  
 
The Srivastava laboratory in collaboration with other groups has also identified a 
720 kb intergenic deletion of ZBTB20 (Figure 1.4) in a patient diagnosed with 
borderline intelligence, attention deficit, impulsivity and frequent mood swings 
(Koul et al., 2013; Rimsky et al., manuscript in preparation). The de novo deletion 
was identified using array comparative genomic hybridization (aCGH) and 
confirmed using a FISH technique with the appropriate probes. The de novo 
intragenic deletion included most of the ZBTB20 transcribed region with the 
exception of the last four exons as shown in Figure 1.4. Recently, several 
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microdeletions in the 3q13 region encompassing the ZBTB20 gene have also 
been identified  (Molin et al., 2012; Vuillaume et al., 2013; Wisniowiecka-
Kowalnik et al., 2013).  
 
 
 
Figure 1.3: The position of the ASD and ID associated variants in the 
ZBTB20 long and short isoforms  
Schematic diagram showing the ZBTB20 long isoform (741 amino acids) and the short 
isoform (668 amino acids) proteins. The ZBTB20 long isoform variant (P46R and 
G419V) and the ZBTB20 short isoform variant (G346V) is indicated. The BTB domain 
(BTB) at the N-terminus and the C2H2 Kruppel-type zinc finger domains (ZnF) at the C-
terminus are shown in both the ZBTB20 isoforms. A region specific to the long isoform 
ZBTB20 (1-73 amino acids) is indicated in orange. 
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Figure 1.4: Schematic diagram showing the location of the deletions, 
duplications and translocation breakpoint region involving the ZBTB20 
gene 
Ideogram of chromosome 3, showing the location of the ZBTB20 gene and neighboring 
genes (DRD3 and GAP43) in the 3q13.2 region. The deletions (Red), duplications (Blue) 
and the breakpoint region (BPR, brown) involving the ZBTB20 gene are indicated with 
the related studies. The shortest region of overlap (SRO) common to the deletions 
shared by more than 15 people is also indicated.  
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ZBTB20 gene is a candidate gene associated with the 3q13.31 
microdeletion and the reciprocal microduplication syndrome 
 
Copy number variations (CNVs) in the proximal long arm of chromosome 3 are 
rare and have been found to be associated with variable phenotypes. Recently 
both deletions and duplications in the 3q13 region, encompassing the ZBTB20 
gene have been identified (Molin et al., 2012). The common phenotypes 
associated with CNVs in this region include developmental delay, increased 
postnatal growth, characteristic facial features and behavioral abnormalities. 
Among all the genes in this region, ZBTB20 is a strong candidate gene 
associated with autism spectrum disorders, intellectual disability and 
developmental delay.  
 
Molin and coworkers (2012) characterized all the 13 previously described 
deletions in the 3q12.3q21.3 region of different sizes as well as identified 15 
novel microscopic or submicroscopic deletions in the 3q12.3q21.3 region using 
various microarray platforms. A deletion map consisting of all the 28 identified 
deletions in the 3q13 region led to the delineation of 3q13.31 as the shortest 
region of overlapping deletion (SRO). 24 patients out of the 28 patients analyzed 
shared an approximately 0.6 Mb of SRO as shown in Figure 1.4. This led to the 
identification of a newly recognized 3q13.31 microdeletion syndrome 
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characterized by developmental delay, muscular hypotonia, a high arched palate, 
distinct facial features including short philtrum and protruding lips.  
 
Recently, additional cases of the 3q13.31 microdeletion syndrome have been 
identified. Wisniowiecka-Kowalnik and coworkers (Wisniowiecka-Kowalnik et al., 
2013) reported a de novo ~4.5-Mb deletion in 3q13.2q13.31 in a 6 year old boy 
with atypical autism, severe developmental delay and intellectual disability 
(Figure 1.4). Further, Vuillaume and coworkers (2013) presented a case of 
3q13.31 microdeletion in a 16-year old girl sharing clinical features commonly 
observed in patients with the 3q13.31 microdeletion syndrome. 
Further, reciprocal microduplications  (Karavitakis et al., 2013; Vuillaume et al., 
2013) to the 3q13.31 microdeletion syndrome have been identified (Figure 1.4). 
These patients with 3q13 microduplication share many overlapping dysmorphic 
features in common with the 3q13.31 microdeletion syndrome patients. 
Karavitakis and coworkers (2013) identified a 3.671 Mb duplication at 
3q13.2q13.31 in a newborn male with clinical features overlapping with 3q13.31 
microdeletion syndrome including dysmorphic features, developmental delay and 
multiple congenital abnormalities. Vuillaume and coworkers (2013) also identified 
a 2.76 Mb microduplication by aCGH in two brothers and their father. The 
phenotype shared by the brothers resembled the phenotype of the 3q13.31 
microdeletion syndrome, including severe intellectual disabilities, developmental 
delay, behavioral abnormalities and obesity. Both these 3q13.31 reciprocal 
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microduplication cases identify ZBTB20 as well as the neighboring gene DRD3 
as the possible candidate genes associated with developmental delay. 
 
Thus, the deletions and duplications described above suggest the ZBTB20 gene 
as well as the neighboring genes including DRD3 in the 3q13 chromosomal 
region as strong candidate genes for developmental delay. Interestingly, both the 
loss and gain in dosage of the ZBTB20 as well as neighboring genes result in 
overlapping symptoms. It is possible that these copy number variations result in a 
dosage imbalance, which can cause failure of neuronal homeostasis, leading to 
these shared clinical phenotypes. Altered gene dosage and impaired neuronal 
homeostasis have been widely implicated in autism spectrum disorders (Toro et 
al., 2010) as well as other neurodevelopmental disorders (Ramocki and Zoghbi, 
2008).   
 
 
SUMOylation- A post-translational modification 
 
SUMOylation is the covalent attachment of Small Ubiquitin-related MOdifier 
(SUMO) proteins to a target protein, in a dynamic and reversible manner. 
SUMOylation regulates protein function in diverse biological processes of the cell 
(Seeler and Dejean, 2003). The first SUMOylated protein to be identified was the 
Ran GTPase-activating protein (RanGAP1) localized exclusively in the cytoplasm 
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(Mahajan et al., 1997; Matunis et al., 1996). Geiss-Friedlander and Melchior 
(2007) showed that SUMOylation of RanGAP1 was responsible for its 
localization to the cytoplasmic fibers of the nuclear pore complex. SUMOylation 
also regulates target protein activity, stability and interaction with other proteins 
(Geiss-Friedlander and Melchior, 2007).  
 
SUMO proteins belong to the ubiquitin-related protein family. Although SUMO 
and ubiquitin share only 18% amino acid identity, they are similar in structure and 
protein folds as determined by nuclear magnetic resonance (NMR) studies 
(Bayer et al., 1998). Like ubiquitin, SUMO proteins are present universally in the 
eukaryotic kingdom. While Saccharomyces, Caenorhabditis and Drosophila have 
one SUMO; humans have four SUMO paralogues, SUMO1, SUMO2, SUMO3 
and SUMO4. SUMO2 and SUMO3 are very similar and have 97% sequence 
identity. However, there is only 47% sequence identity between mature SUMO1 
and SUMO2 or SUMO3. SUMO4 has been identified only in humans in the 
kidney, lymph node and spleen, though its function is still largely unknown 
(Geiss-Friedlander and Melchior, 2007).  
 
The SUMOylation cascade 
 
The SUMOylation cascade is similar to the ubiquitination pathway and involves 
three classes of distinct enzymes, illustrated in Figure 1.5. The SUMO protein is 
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expressed in an immature form and carries a variable stretch of amino acids, 
after the invariant glycine-glycine motif at its C-terminus. The nascent SUMO is 
proteolytically cleaved by SUMO-specific proteases (SENP) to expose the 
glycine-glycine motif at its C-terminus. Mature SUMO is then activated, in an 
ATP-dependent manner by E1 SUMO-activating enzyme (SAE1/SAE2 
heterodimer). The SUMO E1 activating enzyme attaches to the SUMO by a 
thioester bond, formed between the C-terminal glycine of SUMO and the cysteine 
residue of the SAE1 enzyme.  SUMO is then transferred to the catalytic cysteine 
of the Ubiquitin-Conjugating Enzyme E21 (UBE2I) also referred to as UBC9 by a 
thioester bond facilitated by target-specific SUMO-E3 ligases. Finally this leads to 
the formation of an isopeptide bond between the C-terminal glycine residue of 
SUMO and the lysine residue of the target protein. However, the SUMO-
deconjugating enzymes make SUMOylation a highly reversible and dynamic 
process (Geiss-Friedlander and Melchior, 2007).  
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Figure 1.5: Schematic diagram of the reversible SUMOylation pathway 
SUMO protein is proteolytically cleaved by the SUMO-specific protease to expose the C-
terminal di-glycine (GG) motif. Mature SUMO then enters the SUMO-conjugation cycle. 
It is activated by E1 activating enzyme (SAE1/SAE2) in the presence of ATP, resulting in 
the formation of a thioester bond between the catalytic cysteine (C) of SAE2 and the 
glycine (G) of SUMO. SUMO is then conjugated to the E2 conjugating enzyme (UBC9) 
by a thioester bond formed between the catalytic cysteine (C) of UBC9 and the glycine 
(G) of SUMO. UBC9 catalyzes the formation of an isopeptide bond between the lysine 
(K) of the target and the glycine of SUMO, usually in presence of an E3 ligase. The 
SUMO modification is reversible due to the SUMO specific-protease, which disrupts the 
isopeptide bond and releases the SUMO. XX stands for variable stretch of amino acids. 
This figure is redrawn with modifications from Flotho and Melchior, 2013.  
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The SUMO consensus sequence 
 
At least 50% of the SUMO target proteins have a SUMO consensus motif, 
ψKXE/D where Ψ represents large hydrophobic amino acid residues (leucine, 
isoleucine or valine), K, E and D are lysine, glutamic acid and aspartic acid 
respectively while X represents any amino acid. These SUMO consensus motifs 
are directly recognized by SUMO conjugating enzyme UBC9. Some of the 
additional SUMO consensus motifs are: inverted consensus motif, (E/D)XKψ; 
hydrophobic consensus motif, ΨΨΨKXE; phosphorylation-dependent 
SUMOylation motif (PDSM), ΨKXEXX(pS)P; negatively charged amino acid-
dependent SUMOylation motif (NDSM), ΨKXEXXEEEE  and others (Flotho and 
Melchior, 2013) .  
 
Some SUMO substrate proteins also contain a SUMO interaction motif (SIM) that 
helps to recruit the UBC9-SUMO thioester to the target proteins via non-covalent 
interaction with SUMO. In such SIM-dependent SUMOylation, target proteins are 
SUMOylated on multiple lysine residues, which are not necessarily part of the 
SUMO-consensus motifs. The transcriptional corepressor Daxx protein contains 
two independent SUMO-interacting motifs (Santiago et al., 2009), which help in 
mediating its interaction with other proteins. 
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The SUMOylation substrates 
 
SUMOylation targets nuclear proteins, cytoplasmic proteins as well as trans-
membrane proteins. The majority of SUMOylated proteins are nuclear (Seeler 
and Dejean, 2003). In the nucleus, SUMOylation is involved in nuclear trafficking, 
gene expression, genomic stability and chromosomal integrity. The nuclear 
SUMO-substrate proteins are mostly transcription factors, DNA repair proteins, 
replication proteins as well as centromere and kinetochore proteins (Jürgen 
Dohmen, 2004).  
 
The cytoplasmic protein RanGAP1 was the first SUMOylated protein to be 
identified  (Mahajan et al., 1997; Matunis et al., 1996). SUMOylation of RanGAP1 
by SUMO E3 ligase (RanBP2) is known to regulate its localization to the nuclear 
pore complex. Further, SUMOylation regulates the cytoplasmic signal 
transduction proteins, by altering their activity, stability and subcellular 
localization (Jürgen Dohmen, 2004).  
 
The glucose transporters GLUT1 and GLUT4 are two examples of SUMOylated 
transmembrane proteins involved in transporting glucose in the brain (Martin et 
al., 2007). Thus SUMO modifies proteins irrespective of their localization in the 
cell. 
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The biological functions of SUMOylation 
 
A large number of SUMOylated proteins have been identified by biochemical as 
well as genetic screens accompanied by mass spectrometry. However, the 
functional implications of SUMOylation and the mechanisms that regulate it are 
still not completely understood. One widely used experiment to study the function 
of SUMO conjugation to a target protein is by altering the SUMO acceptor lysine 
or the entire SUMO consensus sequence. Other experimental approaches 
involve overexpressing or knocking-down the enzymes in the SUMOylation 
cascade and observing the functional effects on both wild type and mutant 
SUMO substrate.  
 
One of the major functional consequences of SUMOylation is altering the 
transcription regulator activity. Many SUMO substrates are transcription factors 
or transcription co-factors. In many studies, SUMOylation enhances the 
repressive activities of transcription factors including the Forkhead transcription 
factor (FOXL2), Promyelocytic leukemia zinc finger protein (PLZF) and the 
Erythroid Kruppel-like factor (EKLF) (Kang et al., 2003; Kuo et al., 2009; 
Marongiu et al., 2010; Siatecka et al., 2007). It has been shown that 
SUMOylation promotes the interaction of transcription factors with co-repressors  
(Girdwood et al., 2003; Yang and Sharrocks, 2004) leading to transcriptional 
repression activity of target genes. In other cases, SUMOylation results in 
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increased activity of transcriptional activators. For example, the SUMOylation of 
Pax-6 results in increasing its transcriptional activity (Yan et al., 2010).  
 
SUMOylation also regulates protein-protein interaction. SUMOylation helps 
stabilize interaction between proteins and also recruits other proteins with SUMO 
interaction motifs and SUMO consensus motifs to the target protein complex. For 
example, the Promyelocytic leukemia (PML) protein covalently binds SUMO at 
three lysine residues, which helps in recruiting other proteins and eventually 
leads to the formation of nuclear bodies (Zhong et al., 2000).  
 
Understanding the functional effect of SUMOylation on target proteins can be 
challenging. Even for SUMO substrates, where the putative SUMO acceptor 
lysine sites have been confirmed in vivo, finding the functional consequences of 
SUMOylation can be a daunting task. One possible explanation is that, the 
SUMO sites are redundant. The SUMOylated target could be a part of a protein 
complex held together by multiple SUMO binding sites and SUMO interaction 
motifs. Therefore, mutating one SUMO site or even the entire SUMO consensus 
sequence may not have any measurable consequence. 
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SUMOylation of neuronal proteins and its role in synapse formation and 
synaptic activity 
 
As a post-translational modification, SUMOylation is being widely studied in 
neuronal proteins. SUMOylation is involved in many physiological processes 
including neuronal maturation and differentiation as well as neuropathological 
disorders. Both Sumo1 and Ubc9 mRNA are highly expressed in neuronal stem 
cells and in the hippocampal dentate gyrus and pyramidal neurons in rat brain 
(Watanabe et al., 2008). In general, SUMOylation regulates the electrochemical 
signaling in neurons and modulates their synaptic plasticity (Feligioni et al., 
2013). SUMOylation mediates neuronal plasticity through the regulation of 
synaptic signaling and receptor trafficking (Luo et al., 2013). Disruption of 
SUMOylation of neuronal layer-specific transcription factors could also disrupt 
the architecture of neuronal layers in the brain (Gwizdek et al., 2013).  
 
SUMOylation of transcription factors plays a role in synapse formation. The 
functional consequences of SUMOylation are diverse and substrate specific. 
SUMOylation of two proteins Calcium/calmodulin-dependent serine protein 
kinase (CASK) and the Myocyte Enhancer Factor 2A (MEF2A) were shown to 
play an important role in synapse formation and in the development of spines  
(Wilkinson et al., 2010). CASK is a synaptic scaffold protein widely implicated in 
intellectual disability. SUMOylation of CASK by SUMO1 at the K679 residue, 
!
32 
results in reduced spine size and density (Chao et al., 2008). Fusion of SUMO to 
CASK decreases its interaction with the erythrocyte membrane protein band 4.1 
(4.1), resulting in reduced spine size and density (Chao et al., 2008) as it disrupts 
the localization and function of postsynaptic membrane proteins. On the other 
hand, SUMOylation of transcription factor MEF2A promotes synapse formation. 
MEF2A is involved in development of dendritic claws at the presynaptic terminal. 
Covalent conjugation of SUMO1 with MEF2A at residue K403 has been shown to 
regulate synapse formation (Shalizi et al., 2006).  
 
SUMOylation-dependent modulation of synaptic activity is thought to involve both 
postsynaptic and presynaptic proteins. Finally, SUMOylation targets several 
glutamate receptors as well as kainate receptors at both the presynaptic and the 
postsynaptic membrane, and plays an important role in the modulation of 
synaptic activity (Craig and Henley, 2012).  
 
Like other post-translational modifications, SUMOylation can perform diverse 
functions. Determining the effect of SUMOylation on the physiological functions 
performed by ZBTB20 in the developing neurons would provide deeper 
understanding about its role in neurodevelopmental disorders. As the murine 
Zbtb20 dimerizes and is involved in transcriptional regulation, the role of ZBTB20 
SUMOylation on nuclear localization, transcription regulation, dimerization and 
!
33 
stability have been studied. In the future, it would be valuable to determine how 
the SUMOylation of ZBTB20 is regulated in neuronal cells. 
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CHAPTER 2 
 
FUNCTIONAL CHARACTERIZATION OF HUMAN ZBTB20 AND 
IDENTIFICATION OF ZBTB20 INTERACTING PROTEINS 
 
Introduction 
 
Autism spectrum disorder (ASD) and intellectual disability (ID) are frequently 
reported neurodevelopmental disorders with a combined prevalence of 
approximately 3% in the general population (Kim et al., 2011). ASD and ID often 
overlap; 50-70% of patients with ASD also have ID while approximately 10% of 
children with ID show autistic symptoms (Oeseburg et al., 2011). Both ASD and 
ID have a well-established genetic component (Abrahams and Geschwind, 2008; 
Devlin and Scherer, 2012; Ropers, 2010). However the cause is still unknown in 
a majority of ASD and ID cases. 
 
To understand the genetic cause of global developmental delay and autistic 
features in a female child, Srivastava and coworkers (Koul et al., 2013; Rimsky et 
al., manuscript in preparation) characterized an apparently balanced de novo 
translocation t(3;12)(q13.2; p11.2). Two transcription factor genes, BTB (broad 
complex, tramtrack, bric-a-brac)-zinc finger gene, ZBTB20 at 3q13.2 and the 
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SRY (sex determining region Y)-box 5 gene, SOX5, at 12p11.2 were disrupted 
by the translocation breakpoints. This study is focused on the role of ZBTB20 
gene however the role of SOX5 gene was also studied in our laboratory (Rimsky 
et al., manuscript in preparation). 
 
Moreover, several microdeletions encompassing the ZBTB20 gene were 
identified in several patients with ASD and or ASD/ID (Molin et al., 2012; 
Vuillaume et al., 2013; Wisniowiecka-Kowalnik et al., 2013), Two missense 
heterozygous ZBTB20 variations, P46R and G419V were found in patients with 
ASD and or ASD/ID in our laboratory and absent in known databases and 
population-matched controls. These variants were studied in cultured rat cortical 
neurons and observed to affect spine morphology and dendritic arborizations 
(Koul et al., 2013; Rimsky et al., manuscript in preparation). 
 
The ZBTB20 gene is located at chromosomal position 3q13.2. ZBTB20 consists 
of 10 exons, spanning approximately 880 kb of genomic DNA as shown in 
chapter 1 (Figure 1.1). The ZBTB20 gene (also known as DPZF, HOF, Zfp288) 
undergoes alternative splicing and encodes two isoforms of 668- and 741-amino 
acids, both containing a BTB domain at the N-terminal and five C2H2-type zinc 
fingers at the C-terminal. ZBTB20 gene is highly expressed in human fetal brain 
(Koul et al., 2013; Rimsky et al., manuscript in preparation) and murine forebrain, 
cortex and hippocampus (Mitchelmore et al., 2002; Nielsen et al., 2007; Nielsen 
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et al., 2010). ZBTB20 knockout mice show a reduction in the size of the 
hippocampus (Xie et al., 2010) and transgenic mice with ectopic expression of 
ZBTB20 show behavioral abnormalities (Nielsen et al., 2007). These findings 
suggest a potential role of ZBTB20 in the human brain, especially in the 
development of hippocampal neurons. 
 
The ZBTB20 protein is member of the BTB family (Kelly and Daniel, 2006) of 
transcription factors. The BTB domain family belongs to a class of nuclear DNA 
binding transcription factors, involved in biological processes including 
development, differentiation, tumorigenesis and chromatin remodeling (Kelly and 
Daniel, 2006). The murine Zbtb20 protein directly binds and represses the alpha-
fetoprotein gene (Afp) promoter and regulates the expression of the Afp protein 
postnatally in the liver (Xie et al., 2008). The Zbtb20 protein also directly 
represses the fructose-1,6-bisphosphastase 1 (Fbp1) gene, involved in glucose 
stimulated insulin secretion in the pancreatic β-cells. Thus the Zbtb20 protein 
plays a role in regulating glucose homeostasis in mice (Sutherland et al., 2009; 
Zhang et al., 2012). The mouse Zbtb20 has also been shown to repress many 
neocortex layer-specific transcription factor genes in the murine hippocampus 
(Nielsen et al., 2013). Therefore, the BTB and zinc finger protein Zbtb20 acts as 
a transcriptional repressor, involved in regulating gene expression in various cell 
types. 
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The BTB domain containing proteins have been implicated in gene repression 
through conformational changes in the chromatin structure (Costoya, 2007). 
Several BTB domain containing proteins like promyelocytic leukemia zinc-finger 
(PLZF) and B cell lymphomas 6 (Bcl-6) directly interact with co-repressors, 
silencing mediator of retinoid and thyroid receptor (SMRT), the nuclear receptor 
co-repressor (N-CoR), histone deacetylase 1 (HDAC-1) and SIN3 transcription 
regulator family member A (Sin3A) (Privé et al., 2005). These repressors are 
components of the histone deacetylase complex (HDAC), involved in 
transcription repression by removing acetyl groups from the histones. Several 
BTB proteins are also involved in gene repression by binding to components of 
the basal transcriptional machinery like the Drosophila melanogaster BTB 
proteins, bric-a-brac 1 (Bab1) and bric-a-brac 2 (Bab2) involved in the 
development of Drosophila ovaries, legs, antenna and abdomen (Pointud et al., 
2001). Therefore, BTB domain containing proteins are frequently involved in 
transcriptional repression. An important biological property of the BTB and zinc 
finger proteins is protein-protein interaction. The BTB domains mediate both 
homotypic and heterotypic interactions, including BTB and zinc finger proteins 
PLZF and Bcl-6 (Stogios et al., 2005). The BTB and zinc finger proteins 
frequently function as substrate specific adaptors for Cullin E3 ubiquitin ligases, 
targeting substrates to the ubiquitin proteasome pathway (Xu et al., 2003). Thus, 
the BTB and zinc finger family of transcription factors are involved in many 
biological processes in the cell.  
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In this study, I present the functional characterization of human ZBTB20 protein 
in mammalian cells. ZBTB20 has a nuclear localization signal at the N-terminus 
and localizes primarily to the nucleus in mammalian cells. ZBTB20 long and short 
isoforms form homodimers and heterodimers and the N-terminus region 
containing the BTB domain is critical for dimerization. To identify brain expressed 
ZBTB20 interacting proteins, a yeast-two hybrid screen was performed using the 
human fetal brain library and eight novel protein interactions were identified. 
Three of them, NELL2 (neural epidermal growth factor-like 2), LTBP4 (Latent 
transforming growth factor beta binding protein 4), and Granulin precursor, are all 
secreted glycoproteins, which have common epidermal growth factor (EGF)-like 
repeats. Thus the identification of novel ZBTB20 interacting proteins would 
elucidate the physiological functions of the ZBTB20 protein as well as the 
ZBTB20 associated pathways and protein complexes in the human brain.  
 
Materials and Methods 
 
Mammalian expression vectors 
 
ZBTB20 open reading frames corresponding to the ZBTB20 short and long 
isoforms were amplified from the Human Fetal Brain MATCHMAKER cDNA 
library (Clonetech) previously in the laboratory (Rimsky et al., Manuscript in 
preparation). The amplified cDNA constructs were subcloned into the 
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pcDNA3.1/V5-His-TOPO vector, which was tagged with V5 (long and short 
isoform ZBTB20) or GFP (long isoform) using the pcDNA3.1 Directional TOPO 
Expression Kit (Invitrogen). Plasmids were sequenced to confirm and verify the 
insert with vector specific and insert specific primers as shown in Tables 2.1, 
2.2 and 2.3. The constructs were further verified using the TNT T7 Quick 
Coupled Transcription/Translation System (Promega) and the in vitro translated 
proteins were analyzed by SDS-PAGE. The V5-tagged ZBTB20 long and short 
isoform mammalian expression constructs were also verified in vivo by 
transfecting in HEK293H cells. The ZBTB20 mutant plasmid ZBTB20-(BTB)-V5 
lacking the N-terminal BTB domain (1-198 amino acids) of ZBTB20 was 
generated previously in the Srivastava laboratory using Quick Change Site-
Directed Mutagenesis Kit (Stratagene) and sequenced to confirm and verify the 
deletion using vector specific and insert specific primers as shown in Tables 
2.1, 2.2 and 2.3.  
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Table 2.1: Primers used for amplifying ZBTB20 long, ZBTB20 short and  
ZBTB20-(-BTB) constructs 
PRIMER&NAME&& SEQUENCE&5'/3'& Annealing&
Temperature&
(°C)&
Product&
Size&(bp)&
ZBTB20&Long&
isoform&
&F1TTGAAACTACTGAAGAAACCCAAG&
&R1TCCGTCAGACACATGCATCCTCAT&
62& 2223&
ZBTB20&Short&
isoform&
F1ATGACCGAGCGCATTCACAGCATC&
R1TCCGTCAGACACATGCATCCTCAT&
60& 2004&
ZBTB201(1BTB)& F1GATGTGTTCCCGGGGAT&
R1TCCGTCAGACACATGCATCCTCAT&
60& 1629&
 
Table 2.2: ZBTB20 sequencing primers for long and short isoforms  
PRIMER&NAME&& SEQUENCE&5'/3'& Annealing&
Temperature&&
(°C)&
ZBTB20&long&isoform&F& F1TTGAAACTACTGAAGAAACCCAAG& 50&
ZBTB20&4&F& F1CAGCATCCTGCAGATCAAAAC& 50&
ZBTB20&2R& R1GGTGAAAGTCTTGTTGCAGAG& 50&
ZBTB20&long&isoform&R& R1TCCGTCAGACACATGCATCCTCAT& 50&
ZBTB20&Short&isoform&F& F1ATGACCGAGCGCATTCACAGCATC& 50&
&
Table 2.3: Vector primer list  
VECTOR&
NAME&
PRIMER&
NAME&&
&
SEQUENCE&5'/3'& Annealing&
Temperature&
(°C)&
pGBKT7&& BD1F&
BD1R&
F1GGTCAAAGACAGTTGACTGTATCGCCG&
R1CGCCCGGAATTAGCTTGGCTGCAAG&
&
58&
pGADT71Rec& Reamp1AD5’&&
Reamp&1AD3’&
F1GAGATCTTTAATACGACTCACTATAGGGCG&
R1!CAGTATCTACGATTCATCTGCAGCTCGAG& 60&
pcDNA3.1D/
V51HisTOPO&
PC&
BGH&
F1GGGAGACCCAAGCTGGCTAGT&
R1TAGAAGGCACAGTCGAG&
60&
pcDNA3.1/N
T1GFP1TOPO&
NT1GFP&
BGH&
F1CACAATCTGCCCTTTCGAAA&
R1TAGAAGGCACAGTCGAG&
60&
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Yeast two-hybrid screening  
 
A yeast two-hybrid screen was performed using the Matchmaker Gold Yeast 
Two-Hybrid System protocol (Clontech) and the Mate and Plate Human Fetal 
Brain cDNA library. The cDNAs in the Mate and Plate Human Fetal Brain library 
were cloned in the pGADT7-Rec prey vector and pre-transformed in the Y187 
yeast cells (Clontech). Using a TOPO TA cloning kit (Invitrogen), the bait 
plasmid, pGBKT7-ZBTB20 long was constructed by subcloning ZBTB20 long 
isoform cDNA (1-741 amino acids) in the pGBKT7 vector bait vector. The vector 
was sequenced and verified using vector specific primers as shown in Table 
2.3. 
 
The pGBKT7-ZBTB20 long plasmid was then transformed into AH109 yeast 
(MATa strain) using the Frozen-EZ yeast Transformation II kit (Zymo 
Research). The autoactivation and the toxicity analysis were performed by 
mating the pGBKT7-ZBTB20 long bait plasmid with the empty pGADT7-Rec 
prey plasmid plating on single dropout nutritional selection media SD-Trp, 
double dropout nutritional selection media SD-Leu-Trp, triple dropout nutritional 
selection media SD-His-Leu-Trp-X-α-Gal as well as quadruple dropout 
nutritional selection media SD-Ade-His-Leu-Trp-X-α-Gal. The pGBKT7-ZBTB20 
long bait plasmid tested negative for both autoactivation as well as toxicity 
analysis. 
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The ZBTB20 bait plasmid in AH109 was mated to the pre-transformed human 
fetal brain cDNA library in the Y187 yeast strain (MATα strain) by incubating 
overnight at 30°C in enriched YPDA (Yeast Peptone Dextrose Adenine) media. 
Mated yeast was selected by plating on SD-His-Leu-Trp-X-α -Gal as well as 
SD-Ade-His-Leu-Trp-X-α-Gal media and the positive clones were picked.  
 
Plasmid isolation from the positive clones was performed, using the Zymoprep 
Yeast plasmid Miniprep II kit. The ZBTB20 interacting cDNAs in the pGADT7-
Rec plasmid were transformed in the One Shot Top10 (Invitrogen) competent 
bacteria. The cDNA insert in the prey vector was sequenced using the 
pGADT7-Rec specific primers (sequence described above) and submitted to a 
BLAST search. The cDNA’s encoding for an in-frame protein sequence was 
characterized to identify the protein. On-to-one mating between the 
characterized pGADT7-Rec prey vector in Y187 cells and the pGBKT7-ZBTB20 
long bait vector in AH109 yeast cells was performed to verify the interaction. 
The mated yeast cells were plated on triple dropout nutritional selection media 
SD-His-Leu-Trp-X-α-Gal as well as quadruple dropout nutritional selection 
media SD-Ade-His-Leu-Trp-X-alpha-Gal to confirm the interaction.  
 
The control plasmids used for mating were: positive controls, pGBKT7-53 and 
pGADT7-T and negative controls, pGBKT7-Lam and pGADT7-T, provided with 
the MATCHMAKER Gold Yeast Two-hybrid kit (Clontech).  
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Cell culture and transfection 
 
HEK293H cells, a variant of human embryonic kidney cell line 293, were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM; Sigma) 
supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals), 1% 
penicillin/streptomycin (Sigma) and 1% L-glutamine (Sigma) at 37 °C and 5% 
CO2. Approximately 1 million HEK293 cells were plated on Poly-L-Lysine pre-
coated 60 mm dishes and transfected with 3 µg of appropriate plasmids 
(described under co-immunoprecipitation and Western blot analysis in serum- 
and antibiotic-free medium using Lipofectamine 2000 (Invitrogen) according to 
the conditions specified by the manufacturer.  
 
The PC12 cell line, a pheochromocytoma of the rat adrenal medulla, was 
maintained in Ham's F-12K medium (Kaighn's Mod. Corning) supplemented 
with 15% horse serum, 3% FBS (Atlanta Biologicals), 1% penicillin/streptomycin 
(Sigma) and 1% L-glutamine (Sigma) at 37 °C and 5% CO2. The PC12 cells 
were grown in 24 well dishes pre-coated with 1 µg/ml Poly-L-Lysine and 10 
µg/ml laminin. Approximately 150,000 PC12 cells were transiently transfected 
with 1 µg plasmid in serum- and antibiotic-free medium using NeuroMag (OZ 
Biosciences) according to the conditions specified by the manufacturer. The 
PC12 cells were grown in Neural growth factor (NGF) at 0.1 µg/µl 
concentration, for 36-48 hours for differentiation.  
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Immunofluorescence   
 
Cells seeded on coverslips were fixed and permeabilized using 4% 
paraformaldehyde (Sigma) and 0.1% Triton X-100 (ICN Biomedicals) in PBS. 
Cells were then blocked in blocking buffer (0.4% BSA and 2% horse serum in 
PBS) for 30 minutes at room temperature. Blocked cells were then incubated 
with primary antibodies diluted in blocking buffer, at appropriate concentrations 
for 1 hour. The primary antibody, mouse anti-V5 (Invitrogen), was used at a 
1:500 dilution to determine the intracellular localization of the ZBTB20 long 
isoform. Nuclear staining was carried out using 4',6- diamidino-2-phenylindole 
(DAPI; Molecular probes) for 5 minutes. Secondary antibodies used were 
Rhodamine-conjugated anti-mouse IgG and Alexa Fluor 488 Phalloidin, 
incubated for an hour at room temperature. The slips were washed, mounted 
and observed under the fluorescence microscope (Carl Zeiss). The emission 
filters were 594 nm and 488 nm for Rhodamine and Phalloidin-conjugated 
fluorescence, respectively. 
 
Co-immunoprecipitation and Western blot analysis 
 
Approximately 1 million HEK293H cells were grown to approximately 80% 
confluence in 60mm dishes and transfected in serum- and antibiotic-free 
medium using Lipofectamine 2000 (Invitrogen). For the co-immunoprecipitation 
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analysis of the ZBTB20 long isoform with the light chain of MAP1B, 3 µg each 
of GFP-ZBTB20 long/GFP-empty and MAP1BLC1-FLAG were co-transfected in 
the HEK293H cells. For ZBTB20 homo- and hetero-dimerization analysis, GFP-
ZBTB20 long was co-transfected with ZBTB20 long-V5/ ZBTB20 short-V5/ 
ZBTB20 [-BTB]-V5.  
 
48 hours after transfection cells, cells were washed with cold PBS and lysed 
using 1%NP-40 lysis buffer (1% NP-40; 150 mM NaCl; 50 mM Tris [pH 8.0] and 
protease inhibitor cocktail (Sigma) for 10 minutes on ice. Cell lysate was 
sonicated and centrifuged at 12,000 X g at 4 °C to get a clear supernatant. 
Protein concentration was measured using coomassie (Bradford) protein assay 
reagent (Thermo Scientific). 300 µg of protein lysate was pre-cleared and then 
incubated with anti-rabbit magnetic beads (Thermo scientific) pre-coated with 
either 1 µg rabbit anti-V5 antibody (Sigma) or 1 µg rabbit anti-Flag antibody 
(Sigma) in 1% BSA, 1% NP-40 lysis buffer and protease inhibitor cocktail for 4 
hours at 4 °C. The immunoprecipitate-conjugated beads were washed 6 times 
for 10 minutes each at 4 °C in 1% NP-40 lysis buffer and protease inhibitor 
cocktail (Sigma). Protein was eluted by incubating at 95 °C for 3 minutes in 30 
µl 1X Sample Buffer and probed with mouse anti-V5 (Invitrogen) antibody at 
1:5000 dilution, mouse anti-GFP (Santa Cruz) at 1:500 dilution and mouse anti-
FLAG (Sigma) at 1:4000 dilution separately. SuperSignal West Dura (Thermo 
Scientific) was used to detect immunoreactive bands. 
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Results 
 
Intracellular localization of ZBTB20 
 
To determine the subcellular localization of ZBTB20 in mammalian cells, the 
ZBTB20 long isoform was overexpressed in PC12 cells (Figure 2.1). The V5-
tagged ZBTB20 long isoform was transiently transfected in PC12 cells and 
immunofluorescence analysis was performed. Fifty PC12 cells transfected with 
ZBTB20 long-V5 plasmid were analyzed in triplicate. Cells showing only nuclear 
localization of ZBTB20 (Figure 2.1A) were counted and compared with cells 
showing both cytoplasmic and nuclear localization of ZBTB20 (Figure 2.1B) and 
expressed as percentage subcellular distribution. Approximately 80% PC12 
cells transiently transfected with ZBTB20 long isoform showed nuclear 
localization (Figure 2.1.C). Thus, a majority of PC12 cells showed nuclear 
localization of ZBTB20.  
 
Since ZBTB20 was mostly localized to the nucleus of mammalian cells, we 
looked for putative nuclear localization signals in ZBTB20 using PSORT 
analysis (http://psort.hgc.jp/form.html). The analysis revealed that the ZBTB20 
long isoform has a conserved nuclear localization signal 4-KKPK-7, at the N-
terminus (Figure 2.2). However, no nuclear localization signal was predicted in 
the ZBTB20 short isoform. 
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A 
 
B 
 
Figure 2.1: Intracellular localization of ZBTB20 long isoform in PC12 cells 
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C 
 
 
Figure 2.1: Intracellular localization of ZBTB20 long isoform in PC12 cells 
PC12 cells overexpressing ZBTB20 long-V5, immunostained with a, DAPI (blue, 
nucleus); b, Phalloidin (green, cytoplasm); c, V5 antibody (red, ZBTB20 long-V5); d, 
merged image. A. ZBTB20 long-V5 (red) localizes in the nucleus B. cytoplasm. Scale 
bar = 10 µm. The white arrow shows the location of the ZBTB20 long-V5 in the nucleus 
of PC12 cells. The yellow arrow shows the location of the ZBTB20 long-V5 in the 
cytoplasm of PC12 cells. C. Subcellular distribution of ZBTB20 long-V5 in PC12 cells 
analyzed using immunofluorescence staining. Data is represented as percentage of 
PC12 cells showing nuclear and cytoplasmic localization of ZBTB20 long-V5. Error 
bars represent standard deviation from two independent replicates. 
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Figure 2.2: Predicted and conserved nuclear localization signal (NLS) in 
ZBTB20 long isoform 
A. The position of the putative NLS motif and its amino acid sequence is highlighted in 
pink, along with the BTB domain and five zinc fingers in the schematic of the ZBTB20 
long isoform. B. ZBTB20 long isoform sequence (1-51 amino acid only) is aligned 
using HomoloGene. The 4 residue NLS motif (KKPK, in pink) is conserved across 
various species. 
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Homotypic and heterotypic dimerization of ZBTB20 
 
The BTB domain is a well-studied protein-protein interaction domain (Stogios et 
al., 2005). It is has been shown to be responsible for dimerization in various 
BTB domain containing proteins. We co-expressed GFP-tagged ZBTB20 long 
isoform with V5-tagged ZBTB20 short or long isoform in HEK293H cells, to 
determine if ZBTB20 forms homo- or heterodimers. Rabbit anti-V5 antibody was 
used to co-immunoprecipitate the transfected HEK cell protein lysate. Both the 
lysate (L) and immunoprecipitate (IP) were separated on a SDS PAGE gel and 
subjected to Western blot analysis using both ant-V5 and anti-GFP antibody. 
The V5-tagged ZBT20 short isoform as well as the V5-tagged ZBTB20 long 
isoform bind the GFP-tagged ZBT20 long isoform as shown in Figure 2.3. 
Interaction of ZBTB20 long isoform with itself (ZBTB20 long isoform) as well as 
with the ZBTB20 short isoform indicates that the ZBTB20 long isoform forms 
both homodimers and heterodimers in mammalian cells.  
 
To determine whether the N-terminal region containing the BTB domain is 
responsible for ZBTB20 dimerization, we co-expressed GFP-tagged ZBTB20 
long isoform with the N-terminal domain deleted from the ZBTB20, 
ZBTB20 [-BTB]-V5 in HEK293H cells. We observed that the interaction 
between GFP-ZBTB20 long and ZBTB20 [-BTB]-V5 was reduced as compared 
to the interaction between GFP-ZBTB20 long and ZBTB20 long-V5 expressed 
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constructs. As shown in the IP lane in Figure 2.3, the signal detected by 
Western blot analysis using anti-GFP antibody for ZBTB20 [-BTB]-V5 and GFP-
ZBTB20 long co-immunoprecipitation reaction indicates that the ZBTB20 N-
terminus region containing the BTB domain is critical for homo-and heterotypic 
interaction.  
 
Identification of ZBTB20-interacting proteins in human fetal brain 
 
We screened for ZBTB20-interacting proteins in the human fetal brain library 
using the yeast two-hybrid screen (Figure 2.4). ZBTB20 long isoform cDNA 
expressed in frame with the Gal4-DNA binding domain of pGBKT7 was used as 
a bait vector for screening. ZBTB20-interacting colonies, which grew on triple 
dropout SD-His/-Leu/-Trp X-α-gal media as well as higher stringency quadruple 
dropout SD-Ade/-His/-Leu/-Trp X-α-gal media were identified. The bait and the 
prey plasmids were isolated from the yeast, transformed in E. coli and 
sequenced to determine the insert in pGADT7-Rec plasmid. Using translated 
BLAST, blastx and tblastn, cDNA coding for in-frame proteins were determined.  
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Figure 2.3: Homotypic and heterotypic interaction of ZBTB20 long and 
short isoforms 
Western blot analysis of the co-immunoprecipitation reaction of GFP-ZBTB20 long (red 
arrow) co-transfected with ZBTB20 long-V5 (blue arrow) or ZBTB20 short-V5 (orange 
arrow) or mutant ZBTB20-[-BTB]-V5 (green arrow) in HEK293H cells, showing lysate 
(lane L, input) and co-immunoprecipitates (lane IP, immunoprecipitate). As seen in the 
IP lanes (lower pane), GFP-ZBTB20 long is detected in ZBTB20 long-V5 and ZBTB20 
short-V5 IP lanes but weak GFP-ZBTB20 signal is detected in the ZBTB20-[-BTB]-V5 IP 
lane. Anti-V5 antibody (upper panel) and anti-GFP (lower panel) is used for the Western 
blot analysis. Rabbit-anti-V5 antibody is used for pull down. 
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Five clones of Microtubule-associated protein1B Light chain, MAP1BLC1 were 
identified in the ZBTB20 yeast two-hybrid screen. Interaction between ZBTB20 
and MAP1BLC1 in yeast was verified by individually transforming pGBKT7-
ZBTB20 long and pGADT7-MAP1BLC1 plasmid into AH109 and Y197 yeast 
strains respectively followed by one-to-one mating. The mated yeast strains were 
plated on SD-His/-Leu/-Trp X-α-gal and higher stringency SD-Ade/-His/-Leu/-Trp 
X-α-gal media (Figure 2.5B). The growth of mated yeast-harboring ZBTB20 and 
Map1BLC1 plasmids on high stringency nutritional dropout media confirmed the 
interaction between ZBTB20 and MAP1BLC1 in yeast. The interaction of 
ZBTB20 with each of the eight interacting proteins was also similarly confirmed 
by one-to-one mating in yeast (Figure 2.5). The one-to-one yeast mating 
interaction between ZBTB20 and UBC9 (Figure 2.5A) was also confirmed by co-
immunoprecipitation analysis in HEK293H cells (discussed in Chapter 3).  
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Figure 2.4: Schematic diagram of yeast two-hybrid screen using Mate and 
Plate Human fetal brain library 
ZBTB20 long isoform is expressed in the bait plasmid (pGBKT7) having selection for 
tryptophan (Trp) transformed in yeast strain AH109. The human fetal brain library 
expresses cDNA in the prey plasmid (pGADT7-Rec) having selection for leucine (Leu) 
transformed in Y187 yeast strain. Both the cultures are mated to create diploids, which 
have both pGBKT7-ZBTB20 long and human fetal brain cDNA in pGADT7-Rec 
plasmids. HIS3, ADE2 and MEL1 reporter genes are activated in response to protein 
interaction and selected by plating on quadruple dropout media with X-α-Gal (SD-Ade/-
His/-Leu/-Trp X-α-gal). 
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Figure 2.5: UBC9, MAP1BLC1, NELL2, LTBP4, PGRN, CHD3, ZYM5 and 
ZYM2, identified as ZBTB20-interacting proteins using yeast two-hybrid 
screening 
One-to-one yeast mating of pGBKT7-ZBTB20 long in AH109 and (A) pGADT7-UBC9 in 
Y187; (B) pGADT7-MAP1BLC1 in Y187; (C) pGADT7-NELL2 in Y187; (D) pGADT7-
LTBP4 in Y187; (E) pGADT7-PGRN in Y187; (F) pGADT7-CHD3 in Y187; (G) pGADT7-
ZMYM5 in Y187; (H) pGADT7-ZMYM2 in Y187; (I) pGBKT7-53 in AH109 was mated 
with pGADT7-T in Y187 (Positive control); (J) pGBKT7-Lam in AH109 was mated with 
pGADT7-T in Y187 (Negative control). Mated yeast cells were grown on SD-Ade/-His/-
Leu/-Trp X-α gal plates. Only clones with interacting proteins grow on quadruple dropout 
media with X-α Gal (SD-Ade/-His/-Leu/-Trp X-α gal) and turn blue. 
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Table 2.4 shows the eight unique ZBTB20 interacting proteins identified in the 
yeast two-hybrid screen. DAVID (Database for Annotation, Visualization and 
Integrated Discovery; Huang et al. 2007) analysis was performed on all the eight 
ZBTB20 interacting proteins to determine the common Gene Ontology terms. 
The DAVID analysis shows (Table 2.5) that three of the ZBTB20-interacting 
proteins are secreted glycoproteins involved in cell growth regulation. Proteins 
NELL2 (neural epidermal growth factor-like 2) and LTBP4 (latent transforming 
growth factor beta binding protein 4) contain epidermal growth factor-like repeats 
and the protein PGRN (granulin precursor) contains repeats of the 
granulin/epithelin motif.  
 
Table 2.4: List of ZBTB20 interacting proteins identified by the yeast two-
hybrid screen 
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Table 2.5: ZBTB20 interacting proteins grouped using DAVID analysis 
 
 
Discussion 
 
In this study, ZBTB20 long isoform was characterized in mammalian cells. Novel 
brain expressed ZBTB20-interacting proteins were identified using the yeast two-
hybrid screen. Using immunofluorescence analysis of the V5-tagged ZBTB20 
long isoform transfected in PC12 cells, ZBTB20 was found to localize primarily in 
the nucleus. Further, using co-immunoprecipitation analysis in transiently 
transfected HEK293H cells, ZBTB20 long isoform interacted with itself as well as 
with the ZBTB20 short isoform, forming both homodimers and heterodimers. 
Finally the N-terminal region of ZBTB20 containing the BTB domain was 
identified to be important for ZBTB20 dimerization in mammalian cells. 
 
The V5-tagged ZBTB20 long isoform was expressed in PC12 cells and 
immunostained with anti-V5 antibody to determine the localization of ZBTB20 
long isoform. Approximately, 80% of the V5-tagged ZBTB20 transfected PC12 
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cells showed localization to the nucleus. Additional immunofluorescence 
experiments could be performed using primary antibody to the endogenous 
ZBTB20 in various human cell lines. Cell fractionation experiments, followed by 
Western blot analysis against the tagged ZBTB20 or endogenous ZBTB20 could 
further support the localization of ZBTB20 to the nucleus. 
 
Moreover, using PSORT, the ZBTB20 long isoform was predicted to contain a 
conserved nuclear localization signal (NLS) at the N-terminus (4-KKPK-7). 
Previously, Rimsky and coworkers (Rimsky et al., manuscript in preparation) 
demonstrated, nuclear localization of the tagged ZBTB20 short isoform to the 
nucleus of PC12 cells. However a conserved nuclear localization signal in the 
ZBTB20 short isoform could not be identified in this study. This is suggestive of 
the fact that the ZBTB20 short isoform could be transported to the nucleus with 
the help of ZBTB20 long isoform or bound to other proteins, which have nuclear 
localization signals. It is also possible that the ZBTB20 short isoform has a 
nuclear localization signal that could not be identified by the PSORT analysis. 
However, both the ZBTB20 long and the short isoform localize primarily to the 
nucleus of mammalian cells.  
 
Both the long and short isoforms of ZBTB20 have a BTB domain, which is 
approximately 100 amino acids in length. The BTB domain has been shown to be 
involved in protein–protein interaction and mediating transcription regulation 
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(Privé et al., 2005). It is also critical in the homotypic as well as the heterotypic 
interactions between BTB and non-BTB proteins (Bardwell and Treisman, 1994). 
This study shows that the BTB domain is critical in mediating the homo- and 
hetero dimerization of the human ZBTB20 protein. Previous studies by 
Mitchelmore and coworkers (2002) in mice showed that both the long and short 
isoforms of murine Zbtb20 form homo- and heterodimers. They performed in vitro 
GST pull down experiments using both GST tagged as well as 35S-labelled short 
and long isoform mouse Zbtb20 proteins. Using yeast two-hybrid analysis they 
localized the dimerization interface to the BTB domain at the N-terminus of 
murine Zbtb20 long and short isoform proteins. Thus the dimerization of human 
ZBTB20 in the mammalian cells is consistent with the dimerization property of 
the murine Zbtb20 protein.  
 
The interaction between the ZBTB20 long isoform and Microtubule-Associated 
Protein 1B light chain1 (MAP1BLC1) was identified for the first time. Using one-
to-one yeast two-hybrid mating, the interaction between ZBTB20 and MAP1BLC1 
was confirmed in yeast cells. MAP1B is a cytoskeletal protein, highly expressed 
in the developing nervous system. Among other roles, it is involved during the 
elongation phase of axon formation (Gonzalez‐Billault et al., 2004). Moreover 
knockout studies of the MAP1B gene also suggest an important role in the 
development and function of the nervous system (Takei et al., 1997). The 
MAP1B protein encodes a precursor polypeptide of 2464 amino acids, which 
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undergoes proteolytic processing to generate the heavy and light chain, MAP1B-
HC and MAP1B-LC1 respectively (Riederer, 2007). MAP1BLC1 cDNA 
corresponding to amino acids 2137-2445 with respect to the full length MAP1B 
was identified in the yeast two-hybrid screen. Thus ZBTB20 interacts with 
MAP1BLC1 and this interaction further suggests a role of human ZBTB20 in the 
developing brain.  
 
ZBTB20 long isoform interacted with NELL2, PGRN and LTBP4 proteins. Each of 
the three proteins are secreted glycoproteins with Epidermal Growth Factor 
(EGF)-like repeat. EGF-like repeats are an evolutionarily conserved protein 
domain consisting of 30-40 amino acids. The EGF domain includes an 
arrangement of six cysteine residues found mostly in extracellular domain of 
membrane bound proteins or proteins that are secreted. PGRN or Granulin 
Precursor or Granulins functions both as a full-length protein or individual 
granulins. It belongs to a family of secreted, glycosylated peptides that are 
cleaved from a single precursor protein with repeats of granulin/epithelin motif. 
PGRN can act both extracellularly modulating signal transduction pathways, as 
well as intracellularly regulating transcription (Hoque et al., 2010). 
 
The interaction of ZBTB20 with neural epidermal growth factor-like 2 (NELL2) 
was identified in the yeast two-hybrid screen. NELL2 is a glycoprotein containing 
several von Willebrand factor C domains and epidermal growth factor (EGF)-like 
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domains (Kuroda et al., 1999). NELL2 is highly expressed in the mice 
hippocampus and cortex. Studies in mouse suggest that it plays a role in neural 
cell growth and differentiation (Oyasu et al., 2000). It is also involved in neuronal 
signal transduction where it acts as ligand for cell surface receptors.  
 
Further, a TGF β-binding protein 4, LTBP4 was identified in the yeast two-hybrid 
screen. LTBP4 belongs to the latent TGF-β-binding protein (LTP) and fibrillin 
family. It has epidermal growth factor-like repeats (EGF) and eight-cysteine 
repeats. It is involved in controlling and directing the activity of TGFβ1 
(transforming growth factor beta family of cytokines). LTBP4 is deposited in the 
extra cellular matrix (ECM) and forms a complex with TGFβ-like proteins 
(Saharinen et al., 1998). 
 
CHD3, a chromodomain, helicase/ATPase, and DNA-binding domain (CHD) 
family protein was also identified as a ZBTB20 interacting protein. CHD3 is a part 
of the chromatin remodeling and the histone deacetylase complex. It is involved 
in transcription regulation by deacetylating histones (Woodage et al., 1997).  
 
Both Zinc finger proteins, MYM-type 5 (ZYM5) and Zinc finger, MYM-type 2 
(ZYM2) were identified in the yeast two-hybrid screen. ZYM5 and ZYM2 are part 
of the transcriptional corepressor complex, which associates with histone 
deacetylases (HDACs) and other corepressor proteins like CoREST (Gocke and 
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Yu, 2008).  ZYM proteins have been shown to interact non-covalently with SUMO 
and form protein complexes important for formation of PML nuclear bodies 
(Kunapuli et al., 2006). As ZBTB20 functions as a transcriptional repressor and is 
shown to be SUMOylated (Chapter 3), it could potentially form protein complexes 
with ZYM5 and ZYM2 proteins in nuclear bodies. 
 
The identified ZBTB20 interacting proteins could be involved in signaling 
pathways with ZBTB20 or form protein complexes with ZBTB20, possibly 
involved in transcription regulation. The interaction of ZBTB20 with eight novel 
proteins expressed in the human fetal brain cDNA library was confirmed by one-
to-one mating in yeast. The interaction between ZBTB20 and SUMO-conjugating 
enzyme UBC9 was also studied in mammalian cells (Chapter 3). Though the 
interaction of ZBTB20 with MAP1B-LC1, NELL2, LTBP4, CHD3, PGRN, ZYM5 
and ZYM2 was identified in yeast, additional work needs to be done to validate 
these interactions in mammalian cells. Thus, identifying brain-expressed ZBTB20 
interacting proteins is potentially useful for understanding the physiological roles 
of ZBTB20, elucidating its association with neurodevelopmental disorders and 
determining new autism spectrum disorder and intellectual disability associated 
gene
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CHAPTER 3 
 
ZBTB20 INTERACTS WITH THE SUMO-CONJUGATING ENZYME 
UBC9 AND IS A NOVEL TARGET FOR SUMOYLATION 
 
Introduction 
 
SUMOylation is a posttranslational modification which involves covalent 
attachment of Small Ubiquitin-like Modifier (SUMO) to the target protein (Hay et 
al. 2005). There are four SUMO homologs in mammals: SUMO1, SUMO2, 
SUMO3 and SUMO4 (Hay, 2005). SUMO proteins are approximately 100 
amino acids in length and share ~18% sequence identity with ubiquitin. 
However, unlike ubiquitination, SUMOylation does not target a protein for 
degradation. SUMOylation has been shown to regulate transcription, protein 
stability, protein-protein interaction, protein activity and transport of proteins 
between the nucleus and the cytoplasm (Garcia-Dominguez and Reyes, 2009; 
Ouyang et al., 2009). Like ubiquitination, the SUMOylation process is an 
enzymatic cascade, which involves the E1 activating enzyme, E2 conjugating 
enzyme and E3 ligases. The only E2 enzyme identified to date is ubiquitin 
conjugating enzyme E2I (UBC9), which plays a major role in determining 
SUMO substrate specificity and catalyzes covalent attachment of SUMO to 
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target proteins (Geiss-Friedlander and Melchior, 2007). It was observed that 
SUMO target proteins that are recognized by UBC9 usually carry a SUMO 
consensus motif ψKXE/D, where Ψ represents a large hydrophobic residue 
(leucine, isoleucine or valine), K, E and D are lysine, glutamic acid and aspartic 
acid respectively and X represents any amino acid (Hecker et al., 2006; Minty et 
al., 2000; Rodriguez et al., 2001). Additional SUMO consensus sequences 
(Flotho and Melchior, 2013; Matic et al., 2010) including the inverted consensus 
motif (E/DXKΨ), hydrophobic consensus motif (ΨΨΨKXE), phosphorylation-
dependent SUMOylation motif (ΨKXEXX(pS)P) were also identified. These 
consensus sequences can be SUMOylated in vitro under high UBC9 
concentration in the absence of the SUMO E3 ligases. Thus the SUMO 
conjugating enzyme UBC9 plays an important role in SUMO consensus site-
directed SUMOylation (Flotho and Melchior, 2013). 
 
ZBTB20 belongs to the BTB (Broad-Complex, Tramtrack, and Bric-a-brac) zinc 
finger family of transcription factors. The ZBTB20 gene has two alternative 
translation initiation sites encoding the ZBTB20 long and short isoforms, 741- 
and 668 amino acids respectively. Both the ZBTB20 isoforms are highly 
expressed in the developing human fetal brain, especially in the fetal 
hippocampus (Rimsky et al. manuscript in preparation; Nielsen et al. 2013).       
Murine Zbtb20 is also highly expressed in the hippocampus and is involved in 
hippocampal neurogenesis, specifically in the determination of hippocampal CA1 
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field identity (Mitchelmore et al., 2002; Nielsen et al., 2007; Nielsen et al., 2013). 
Zbtb20 null mice show a reduction in size of the hippocampus as compared to 
wild type mice (Xie et al., 2010). Mice with ectopic expression of Zbtb20 in non-
hippocampal fields show hippocampus-like corticoneurogenesis and behavioral 
abnormalities (Nielsen et al., 2007). Moreover, murine Zbtb20 functions as a 
transcriptional repressor. Using the targeted deletion of Zbtb20 in different cell 
types, Zbtb20 acts as a repressor of target genes (Nielsen et al., 2013; 
Sutherland et al., 2009; Xie et al., 2008; Zhang et al., 2012). 
 
To elucidate the physiological roles of ZBTB20 in the human brain and identify 
brain expressed ZBTB20 interacting proteins, a yeast-two-hybrid screen was 
performed using ZBTB20 long isoform as bait (Chapter 2). This study describes 
the interaction between ZBTB20 and SUMO conjugating enzyme UBC9 in 
mammalian cells. Consistent with its interaction with UBC9, two putative 
conserved SUMO consensus sites at lysine 330 (K330) and lysine 371 (K330) 
were identified in ZBTB20. Further, the interaction of ZBTB20 with SUMO1 was 
observed in HEK293H cells and the ZBTB20 K330 residue was found to be 
critical for SUMO1 binding. Altering ZBTB20 K330 or the entire SUMO 
consensus motif abolished ZBTB20 SUMOylation. The biological consequences 
of ZBTB20 SUMOylation were also elucidated. Both wild type ZBTB20 and 
ZBTB20 SUMOylation mutants showed the same intracellular localization, 
transcription repression activity and stability. Surprisingly, the ZBTB20 long 
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isoform SUMOylation mutant K330R, failed to dimerize with the wild type 
ZBTB20. Since dimerization is critical for the functioning of BTB proteins 
(Stogios et al., 2005), SUMOylation could potentially play a significant role in 
regulating the physiological functions of ZBTB20 in the brain.  
 
Material and Methods 
 
Plasmids 
 
The ZBTB20 open reading frame corresponding to the short (668 aa) and long 
(741 aa) isoforms was amplified from Human Fetal Brain MATCHMAKER cDNA 
library (Clonetech). The amplified cDNA was subcloned into pcDNA3.1/V5-His-
TOPO vector, with V5 tag (long and short isoform) or GFP tag (long isoform) 
using the pcDNA3.1 Directional TOPO Expression Kit (Invitrogen). Site-directed 
mutagenesis using the QuikChange II Site-Directed mutagenesis kit 
(Stratagene) was performed to generate the following ZBTB20 SUMO mutants 
constructs: ZBTB20 K330R, Δ330, Δ327-333, K371R, Δ371 and Δ368-374 as 
shown in Table 3.1. All constructs were sequenced to confirm and verify the 
alteration. Constructs were further verified using the TNT T7 Quick Coupled 
Transcription/Translation System (Promega) and analyzed by SDS-PAGE. 
UBC9 cDNA was also amplified from the Matchmaker Human Fetal Brain 
Library (Clontech) and subcloned into pcDNA3.1/N-terminal-GFP-TOPO vector 
!
88 
using NT-GFP Fusion TOPO TA Expression Kit (Invitrogen). The GFP-UBC9 
construct was sequenced using vector specific primers.  
 
Table 3.1: Primers used to generate ZBTB20 SUMOylation mutant 
constructs in pcDNA3.1/V5-His-TOPO vector  
Primer&Name&& Primer&Sequence& Annealing&
Temperature&
(°C)&
ZBTB20&K330R& F1AGTGGGCAACATCCACATCAGGCAGGAGATGG&
R1CCATCTCCTGCCTGATGTGGATGTTGCCCACT&
50&
ZBTB20&Δ330& F1GGCAACATCCACATCCAGGAGATGGAGGAC&
R1GTCCTCCATCTCCTGGATGTGGATGTTGCC&
50&
ZBTB20&Δ327/333& F1GACCCTAGTGGGCAACGAGGACGATTACGACT&
R1AGTCGTAATCGTCCTCGTTGCCCACTAGGGTC&
50&
ZBTB20&K371R& F1CACCGAGAGTGAGCCCAGAGGTGAAAGCTTCG&
R1CGAAGCTTTCACCTCTGGGCTCACTCTCGGTG&
50&
ZBTB20&Δ371& F/&CCGAGAGTGAGCCCGGTGAAAGCTTCGA&
R1TCGAAGCTTTCACCGGGCTCACTCTCGG&
50&
ZBTB20&Δ368/374& F/&CGAGGGCACCGAGTTCGACTCGGGCG&
R1&CGCCCGAGTCGAACTCGGTGCCCTCG&
50&
!
Yeast two-hybrid screening  
 
A yeast- two-hybrid screen was performed using Matchmaker Gold Yeast Two-
Hybrid System protocol (Clontech) and the pre-transformed Mate and Plate 
Human Fetal Brain library (Clontech). The ZBTB20 long isoform cDNA was 
subcloned into the pGBKT7 vector using a TOPO TA cloning kit (Invitrogen). 
pGBKT7-ZBTB20 was used to transform the AH109 yeast strain using the 
Frozen-EZ yeast Transformation II kit (Zymo Research) which was then mated 
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to the human fetal brain cDNA library pre-transformed in the Y187 yeast strain. 
Mated yeast were selected for the ZBTB20-interacting colonies by plating on 
triple dropout synthetic media, SD-His-Leu-Trp-X-α-Gal as well as quadruple 
dropout synthetic media SD-Ade-His-Leu-Trp-X-α-Gal. Blue colonies that grew 
on these triple and quadruple dropout nutritional selection media were identified 
and the interacting cDNA’s were isolated and sequenced. Plasmid isolation 
from the selected colonies was performed using the Zymoprep II- Yeast plasmid 
Miniprep kit. The isolated prey plasmid was transformed using One Shot Top10 
(Invitrogen) competent cells. By sequencing using prey vector-specific primers, 
full length UBC9 cDNAs were identified from the yeast two-hybrid screen. 
pGADT7-Rec UBC9 plasmid was used to transform the Y187 yeast strain which 
was mated individually with pGBKT7-ZBTB20 long isoform  in AH109 yeast 
strain and grown on nutritional dropout media to confirm interaction. The control 
plasmids used for mating were: positive controls, pGBKT7-53 and pGADT7-T 
and negative controls, pGBKT7-Lam and pGADT7-T provided with the 
MATCHMAKER Gold Yeast Two-hybrid kit (Clontech).  
 
Cell culture and transfection 
 
HEK293H cells, a variant of human embryonic kidney cell line 293, were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM; Sigma) 
supplemented with 10% fetal bovine serum (Atlanta Biologicals), 1% 
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penicillin/streptomycin (Sigma) and 1% L-glutamine (Sigma) at 37°C and 5% 
CO2. Approximately, one million HEK293H cells were plated on Poly-L-lysine 
coated 60 mm dishes and transfected with 3 µg plasmid in serum-and antibiotic 
free DMEM media using Lipofectamine 2000 (Invitrogen) according to the 
conditions specified by the manufacturer. 
 
Rat primary neuronal cultures were isolated from cortical hemispheres dissected 
from one-day-old Sprague Dawley rats, maintained at Lander University. Cells 
from the rat cortices were suspended in media reconstituted by mixing 
Neurobasal media (Invitrogen), 2% B27 (Invitrogen), 1% penicillin/streptomycin 
(Sigma) and 1% L-glutamine (Sigma). Primary neuronal cells were maintained in 
the media supplemented with growth factors including epidermal growth factor 
(EGF, Millipore) and fibroblast growth factor (FGF, Millipore) added to the media 
at 20 ng/ml each. The cells were then plated on coverslips for 
immunofluorescence analysis (described below) and transfected with 1 µg 
plasmid DNA using Lipofectamine LTX with Plus reagent (Invitrogen) in 
DME/F12 media (Millipore) according to the conditions specified by the 
manufacturer. 
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Immunofluorescence analysis  
 
Rat primary neuronal cells were seeded on Poly-L-lysine pre-coated coverslips 
in neural basal media with 5% FBS (Sigma). Approximately 2-3 days post-
plating, cells were transfected with following plasmids: V5-tagged wild type 
ZBTB20 long isoform or ZBTB20 SUMO double mutant plasmids (ZBTB20 
K330R, K371R and ZBTB20 Δ327-333, Δ368-374) in pcDNA3.1/V5-His-TOPO 
vector, were transfected for localization studies. GFP-UBC9 and V5-ZBTB20 
long isoform plasmids were cotransfected for colocalization analysis. The 
primary neuronal cell transfections were performed in DME/F-12 (Life 
Technologies) and Neural Basal media (Millipore) with Lipofectamine LTX and 
plus reagent (Invitrogen), according to the conditions specified by the 
manufacturer. Four days post-transfection, immunofluorescence analysis was 
performed.  The transfected cells seeded on coverslips were fixed using 4% 
paraformaldehyde for 30 minutes at room temperature followed by 
permeabilization using 0.1% Triton X-100 (ICN Biomedicals) for 5 minutes. 
Cells were incubated in blocking buffer (0.4% BSA and 2% horse serum in 
PBS) for 30 minutes at room temperature. Following primary antibodies were 
mixed together at the indicated dilutions for double staining the cells: mouse 
anti-V5 (Invitrogen) at 1:500 dilution and rabbit anti-GFP (Roche) at 1:400 
dilution; mouse anti-V5 (Invitrogen) at 1:500 dilution and rabbit anti-Neuronal β-
tubulin (Covance) used at 1:3000 dilution. Secondary antibodies used were 
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Rhodamine-conjugated, Alexa Fluor chicken anti-mouse 594 at 1:2000 dilution 
and FITC-conjugated Alexa Fluor chicken anti-rabbit 488 at 1:800 dilution. 
Nuclear staining was performed by incubating the cells in 4',6- diamidino-2-
phenylindole (DAPI; Molecular probes) for 5 minutes. The slips were washed in 
PBS, mounted on a glass slide using ProLong Gold antifade reagent 
(Invitrogen). The slides were observed under a fluorescence microscope.  
 
Co-immunoprecipitation and Western blot analysis 
 
HEK293H cells were grown in Poly-L-Lysine coated 60mm dishes and 
transiently transfected with 3 µg of the appropriate V5-tagged and GFP-tagged 
plasmids in serum- and antibiotic-free medium using Lipofectamine 2000 
(Invitrogen). Approximately 48 hours post-transfection, cells were washed with 
cold PBS and lysed using 1%NP-40 lysis buffer [1% NP-40; 150 mM NaCl; 50 
mM Tris (pH8.0)] and protease inhibitor cocktail (Sigma) for approximately 15 
minutes on ice. Cell lysate was sonicated and centrifuged at 12,000 X g at 4 °C 
to get a clear supernatant. Protein concentration was measured using 
coomassie (Bradford) protein assay reagent (Thermo Scientific). Approximately 
300 µg of protein lysate was pre-cleared and then incubated with anti-rabbit 
magnetic beads (Thermo scientific) pre-coated with 1 µg anti-V5 antibody (anti-
rabbit, Sigma) in 1% BSA and 1% NP-40 lysis buffer and protease inhibitor 
cocktail for 4 hours at 4°C. The immunoprecipitate-conjugated beads were 
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washed 6 times for 10 minutes each at 4 °C in 1% NP-40 lysis buffer and 
protease inhibitor cocktail (Sigma). Protein was eluted by incubating at 95°C for 
3mins in 30µl 1X sodium dodecyl sulphate (SDS) sample buffer.  Both lysate 
and co-immunoprecipitate were separated on SDS-PAGE gel and probed with 
mouse anti-V5 (Invitrogen) antibody at 1:5000 dilution and mouse ant-GFP 
(Santa Cruz) at 1:500 dilution separately at 4°C. SuperSignal West Dura 
(Thermo Scientific) was used to detect immunoreactive bands.  
 
Preparation of protein extracts for SUMOylation 
 
Approximately 1 million HEK293H cells were plated on Poly-L-lysine coated 60 
mm dishes in DMEM media supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin and 1% L-glutamine. After 48 hours post-transfection, 
cells were harvested for 10min on ice by scrapping in 1% NP-40 lysis buffer, 1X 
protease inhibitor cocktail and 40mM N-Ethylmaleimide (NEM; Sigma). Cell 
lysate was sonicated, centrifuged and boiled in SDS sample buffer. The 
following antibodies were then used for Western blot analysis: mouse anti-V5 
(Invitrogen) at 1:5000 dilution, rabbit anti-SUMO1 (Enzo) at 1:1000 dilution and 
mouse anti-alpha tubulin (Santa Cruz) at 1:1000 dilution. 
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Gal4-based transcriptional assay 
 
Approximately 2.3X105 HEK293H cells were plated on a Poly-L-lysine coated 12-
well dish in DMEM media supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin and 1% L-glutamine. Reporter plasmids, pG5-SV40 Luc 
(firefly luciferase, 200 ng) and pRL-TK (Renilla luciferase control reporter, 5 ng), 
were cotransfected along with 100 ng of Gal4-driven ZBTB20 long isoform wild 
type (Gal4-ZBTB20 pCMV-FA), ZBTB20 SUMO mutant plasmid (Gal4-ZBTB20 
K330R pCMV-FA, Gal4-ZBTB20 K371R pCMV-FA, Gal4-ZBTB20 K330R, 
K371R pCMV-FA) or control plasmid (Gal4-pCMV-FA) using Lipofectamine 2000 
as per conditions specified by the manufacturer.  
 
Approximately 24 hours post-transfection cells were washed in PBS and lysed in 
Passive Lysis buffer (Promega) by freeze-thaw protocol. Cells were scrapped 
and then centrifuged to remove cell debris. Using a GloMax Microplate 
luminometer with dual injectors (Promega) loaded with Luciferase Assay 
Reagent (LARII, Promega) and Stop and Glow reagent (Promega), both firefly 
and Renilla luciferase readings were obtained from the cell lysate. Readings 
were measured in triplicate at the same condition. Further, the firefly luciferase 
activity was normalized with the Renilla luciferase activity and expressed as 
relative fold luciferase activity. 
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Cycloheximide stability assay 
 
For the cycloheximide (CHX) stability assay, approximately one million HEK293H 
cells were plated on Poly-L-lysine coated 60 mm dishes. Cells were transfected 
with 3 µg of V5-tagged ZBTB20 wild type or SUMO acceptor lysine mutant 
plasmids, ZBTB20 K330R and ZBTB20 K371R. About 12 hours post-
transfection, HEK293H cells in the 60mm dishes were counted and split into a 12 
well plate such that each well had approximately 2 X105 cells. After 18-20 hours 
post-plating, cells were treated with 100 µg/ml of Cycloheximide (CHX), 
reconstituted in dimethyl sulfoxide (DMSO), or in DMSO alone (control wells) for 
36 hours. The cells were harvested at the time of treatment (time 0), and 36 
hours post-treatment (time 36) by incubating the cells in 1% NP-40 lysis buffer 
and protease inhibitor cocktail. The protein concentration in the lysate was 
measured using coomassie (Bradford) protein assay reagent (Thermo Scientific). 
An equal amount of protein from all the wells were separated on a SDS-PAGE 
gel and subjected to Western blot analysis using anti-V5 antibody to detect 
ZBTB20 wild type and ZBTB20 SUMO mutants. The membrane was reprobed 
with anti-GAPDH antibody to show equal protein loading. 
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Results 
 
Identification of UBC9 as a ZBTB20-interacting protein by yeast two-
hybrid 
 
To increase our understanding of the physiological function of ZBTB20, a yeast 
two-hybrid screen was performed to search for brain expressed ZBTB20- 
interacting proteins. The full-length human ZBTB20 long isoform was fused to 
the Gal4 DNA binding domain to serve as a bait (Figure 3.1A), to screen the 
Mate and Plate Human Fetal Brain cDNA library in pGADT7-rec vector. Blue 
colonies, which grew on nutritional triple dropout SD-His/-Leu/-Trp X-α-gal 
media, as well as higher stringency quadruple dropout SD-Ade/-His/-Leu/-Trp 
X-α-gal media, were selected. Plasmids from the selected colonies were 
isolated by transforming in E. coli and sequenced to identify the ZBTB20-
interacting cDNAs. Eight unique ZBTB20- interacting proteins were identified in 
the yeast two-hybrid screen (Chapter 2), though the focus of this study is the 
interaction of ZBTB20 with SUMO conjugating enzyme UBC9.  
 
Three full-length UBC9 cDNA clones (Figure 3.1B) were identified in the 
ZBTB20 yeast two-hybrid screen. Interaction between ZBTB20 and UBC9 in 
yeast was verified by one-to-one mating, by individually transforming pGBKT7-
ZBTB20 long isoform and pGADT7-UBC9 plasmids into AH109 and Y197 yeast 
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strains respectively followed by mating the two yeast strains and further plating 
on SD-Ade/-His/-Leu/-Trp X-α-gal media (Figure 3.1C).  The strength of 
ZBTB20 and UBC9 interaction was determined by measuring beta-
galactosidase activity using the yeast liquid β-galactosidase assay (Figure 
3.1D). The growth of mated yeast harboring ZBTB20 and UBC9 plasmids on 
high stringency nutritional dropout media and its beta-galactosidase expression 
levels confirmed the potential interaction between ZBTB20 and UBC9 in yeast. 
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Figure 3.1: ZBTB20 interacts with UBC9 in a yeast two-hybrid assay  
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Figure 3.1: ZBTB20 interacts with UBC9 in a yeast two-hybrid assay  
 (A) Schematic representation of the BTB domain (BTB) and five zinc finger domains 
(Znf) in the long isoform of ZBTB20. Orange box at N-terminus indicates region (1-73 
aa) specific to the long isoform (B) Full length UBC9 (158 aa) identified in yeast two-
hybrid screen. (C) Yeast mating of pGBKT7-ZBTB20 in AH109 and pGADT7-UBC9 in 
Y187, pGBKT7-53 in AH109 and pGADT7-T in Y187 (Positive control) and pGBKT7-
Lam in AH109 and pGADT7-T in Y187 (Negative control). Mated yeast cells were 
grown on SD-Ade/-His/-Leu/-Trp X-α gal plates. (D) Liquid beta-galactosidase assay to 
measure the strength of interaction between pGBKT7-ZBTB20 and pGADT7-UBC9. 
Error bars represent standard deviation from three independent replicates. 
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ZBTB20 interacts with UBC9 in mammalian cells 
 
To further confirm the interaction between ZBTB20 and UBC9 in mammalian 
cells, a co-immunoprecipitation analysis was carried out. HEK293H cells were 
transiently transfected with V5-tagged ZBTB20 long isoform and GFP-tagged 
UBC9 expression vectors. The HEK293H cell lysates were prepared and 
immunoprecipitated using rabbit anti-V5 antibody followed by Western blot 
analysis using anti-V5 antibody (Figure 3.2, upper panel) and anti-GFP antibody 
(Figure3.2, lower panel). As shown in Figure 3.2, ZBTB20 long isoform-V5 
interacted with GFP-UBC9, validating the interaction between wild type ZBTB20 
long isoform and SUMO conjugating enzyme UBC9. 
 
To determine the UBC9 binding region of ZBTB20, ZBTB20 lacking the N-
terminal region including the BTB domain, ZBTB20-(-BTB)-V5 was coexpressed 
with GFP-UBC9 in HEK293H cells, followed by Western blot analysis of the 
lysates and immunoprecipitates. GFP-UBC9 was not detected in the 
immunoprecipitate (Figure 3.2), indicating that the N-terminus region of ZBTB20 
is critical for UBC9 binding. The BTB domain was shown to mediate protein-
protein interactions in members of the BTB family of transcription factors 
(Stogios et al., 2005). 
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Figure 3.2: ZBTB20 interacts with UBC9 in mammalian cells and the N-
terminal of ZBTB20 is critical for its interaction with UBC9 
Western blot analysis of the co-immunoprecipitation reaction of ZBTB20 long-V5 (red 
arrow) or ZBTB20-(-BTB)-V5 (purple arrow) with GFP-UBC9 (blue arrow), showing 
lysate (lane L, input) and co-immunoprecipitates (lane IP, immunoprecipitate). Anti-V5 
antibody (upper panel) and anti-GFP (lower panel) is used for the Western blot 
analysis. GFP empty vector (green arrow) is used as negative control.  
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To investigate the co-localization of ZBTB20 and UBC9 in mammalian cells, 
immunofluorescence analysis was performed in rat primary neuronal cells 
(Figure 3.3). GFP-tagged UBC9 and V5-tagged ZBTB20 long isoform were 
coexpressed in the rat primary neuronal cells followed by immunofluorescence 
analysis, using antibodies against the GFP and V5 tags. Co-localization of 
ZBTB20 long isorm-V5 and GFP-UBC9 was indicated by yellow/orange signal 
detected in the nucleus, cytoplasm and neurite processes of primary neuronal 
cells (Figure 3.3). However, coexpression of V5-tagged LacZ construct 
(negative control, not shown) with GFP-tagged UBC9 failed to co-localize in the 
rat primary neuronal cells. The interaction between ZBTB20 long isoform and 
UBC9 in HEK293H cells was also specific (GFP-empty vector failed to interact 
with ZBTB20-V5), indicated by co-immunoprecipitation analysis. Thus from the 
co-immunoprecipitation and co-localization experiments in mammalian cells, we 
concluded that ZBTB20 and UBC9 interact in vivo. 
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Figure 3.3: ZBTB20 long isoform co-localizes with SUMO conjugating 
enzyme UBC9 
ZBTB20 long-V5 and GFP-UBC9 co-expressed in rat primary neuronal cells. (I) Blue 
(DAPI; nucleus); (II) green (GFP-UBC9); (III) red (ZBTB20 long-V5); (IV) co-localization 
indicated by yellow/orange signal. Scale bar = 10µm. 
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ZBTB20 is SUMOylated and co-localizes with SUMO1 
 
We hypothesized that ZBTB20 is SUMOylated as it interacts with UBC9, an 
enzyme involved in the conjugation of SUMO to target proteins. A majority of 
SUMOylated proteins have a consensus SUMOylation motif, ΨKXE. Using 
SUMOylation site prediction software seeSUMO (Teng et al., 2012) and 
SUMOsp 2.0 (Ren et al., 2009), two putative consensus SUMOylation motifs, 
IK330QE and PK371GE (Figure 3.4A) in the ZBTB20 long isoform at conserved 
lysine residues, K330 and K371, were predicted. Furthermore, the SUMOylation 
site prediction software seeSUMO predicted that ZBTB20 long isoform K330 
residue had a higher SUMO binding score than the K371 residue, as shown by 
a high classifier output and confidence level values in Figure 3.4B. Both of 
these putative SUMOylation motifs are well conserved in ZBTB20 orthologues 
as shown in Figure 3.4C, suggesting that SUMO modification of these motifs 
could be functionally significant.  
 
 
 
 
 
 
 
!
105 
A 
 
B 
 
C 
 
Figure 3.4: Predicted human ZBTB20 long isoform SUMOylation sites 
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Figure 3.4: Predicted human ZBTB20 long isoform SUMOylation sites 
 (A) Schematic of ZBTB20 showing two SUMO consensus motifs. SUMO consensus 
sequences at K330 and K371, shown in red, between BTB domain and five zinc finger 
domains (Znf). (B) SUMOylation residues, K330 and K371 scored on the basis of 
classifier output and confidence level using seeSUMO. (C) Region surrounding the two 
putative SUMOylation motifs, IK330QE and PK371GE (red box) aligned in ZBTB20 
orthologues using Homologene.  
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V5-tagged ZBTB20 long isoform and HA-tagged SUMO1 were transiently 
transfected in HEK293H cells to determine ZBTB20 SUMOylation in vivo. Cells 
were lysed in NP-40 lysis buffer and N-ethylmaleimide (NEM), a SUMO 
protease inhibitor. NEM is a sulfhydryl reagent that ablates the enzyme function 
of cysteine proteases, preventing deSUMOylation. Western blot analysis of the 
protein lysate using anti-SUMO1 or anti-V5 antibody was performed. 
Expression of wild type ZBTB20 with SUMO1 yielded two additional higher 
molecular weight bands when probed with either anti-V5 or anti-SUMO1 
antibody (Figure 3.5, lane 1), suggesting that ZBTB20 is modified by SUMO1. 
 
The ZBTB20 lysine 330 and lysine 371 residues were mutated (K330R or 
K371R) or individually deleted (Δ330K or Δ371K), or deleted for the 7 amino 
acid conserved sequence surrounding both the lysine residues (Δ327-333 or 
Δ368-374), to investigate the SUMO acceptor lysine residue involved in 
ZBTB20 SUMOylation. HEK293H cells were co-transfected with ZBTB20 
SUMO mutant constructs and SUMO1 and protein lysates were prepared as 
described above. Lysine 330 mutations, K330R, Δ330K, and Δ327-333 showed 
the absence of the higher molecular weight bands (Figure 3.5, lane 2, lane 3 
and lane 4) detected both in ZBTB20 wild type as well as in mutations involving 
the lysine 371 residue: ZBTB20 K371R, Δ371K or Δ368-374 (Figure 3.5, lane 5, 
lane 6 and lane 7) as shown by Western blot analysis using anti-SUMO1 or 
anti-V5 antibody. Mutations involving the ZBTB20 K330 residue failed to show 
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the higher molecular weight bands in the presence of SUMO1, it is thus likely 
that ZBTB20 K330 is the site of SUMO1 binding.  
 
 
 
Figure 3.5: Lysine 330 is likely the site of SUMO1-conjugation in ZBTB20 
Western blot analysis of HEK293H lysates overexpressing HA-SUMO1 and ZBTB20 
long-V5 or ZBTB20 SUMOylation mutants probed with anti-V5 (upper panel), anti-
SUMO1 (middle panel) or anti α-Tubulin (lower panel). Two slower migrating bands 
(indicated by arrows) are observed in lane 1 (ZBTB20 long-V5 wild type) but not in lane 
2 (∆327-333), lane 3(∆330) and lane 4 (K330R). Bands similar to wild type but lighter in 
intensity were observed in lane 5 (∆368-374), lane 6 (∆371) and lane 7(K371R). * 
Nonspecific band. Anti-α-Tubulin is used as loading control. 
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To investigate whether ZBTB20 and SUMO1 co-localize in mammalian cells, 
both V5-tagged ZBTB20 long isoform and HA-tagged SUMO1 constructs were 
transfected in HEK293H cells. Immunofluorescence analysis was performed 
using anti-SUMO1 and anti-V5 antibodies and co-localization was detected by 
the presence of yellow/orange signal in the nucleus of HEK293H cells as shown 
in Figure 3.6. 
 
ZBTB20 SUMO mutants do not affect the nuclear localization of ZBTB20 
 
It is known that SUMOylation of SUMO target proteins can regulate their 
subcellular localization, which in turn regulates protein function as well as 
protein-protein interaction in the cell (Lomelí and Vázquez, 2011; Marongiu et 
al., 2010).  
 
The ZBTB20 long isoform localizes primarily in the nucleus as described in 
Chapter 2. Since SUMOylation is involved in targeting SUMO substrates to the 
nucleus, we hypothesized that SUMOylation regulates the nuclear localization 
of ZBTB20. To test this hypothesis, V5-tagged ZBTB20 long isoform (Figure 
3.7A), SUMO acceptor lysine double mutant ZBTB20 long K330R, K371R 
(Figure 3.7B) and ZBTB20 SUMO consensus double mutant ZBTB20 long 
Δ327-333, Δ368-374 (Figure 3.7C) were transiently overexpressed in rat 
primary neuronal cells and in HEK293H cells (not shown). In both the 
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mammalian cells lines, wild type ZBTB20 as well as the ZBTB20 SUMO 
mutants was primarily localized in the nucleus. Figure 3.7 shows the nuclear 
localization of wild type and SUMOylation mutant ZBTB20 in rat primary 
neuronal cells. Thus, contrary to our hypothesis, SUMOylation did not appear to 
be necessary for the nuclear location of ZBTB20 in mammalian cells.  
 
 
 
Figure 3.6: ZBTB20 long isoform co-localizes with SUMO1 
HEK293H cells overexpressing HA-SUMO1 and ZBTB20 long-V5 constructs. (a) Blue 
(DAPI, nucleus); (b) green (SUMO1); (c) red (V5-epitope, ZBTB20); (d) merged image. 
Co-localization is indicated by yellow/orange signal in nucleus. Scale bar = 10µm. 
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A. ZBTB20 long-V5 
 
Figure 3.7: Both ZBTB20 wild type and ZBTB20 SUMO acceptor site 
mutants localize in the nucleus of rat primary neuronal cells 
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B. ZBTB20 long K330R, K371R -V5 
 
Figure 3.7: Both ZBTB20 wild type and ZBTB20 SUMO acceptor site 
mutants localize in the nucleus of rat primary neuronal cells 
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C. ZBTB20 long Δ327-333, Δ368-374 -V5 
 
 
Figure 3.7: Both ZBTB20 wild type and ZBTB20 SUMO acceptor site 
mutants localize in the nucleus of rat primary neuronal cells 
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Figure 3.7: Both ZBTB20 wild type and ZBTB20 SUMO acceptor site 
mutants localize in the nucleus of rat primary neuronal cells 
 (A) Wild type ZBTB20 long-V5, (B) ZBTB20 SUMOylation double mutant (K330R in 
SUMO consensus motif 1 and K371R in SUMO consensus motif 2) and (C) ZBTB20 
SUMOylation double mutant deleted for entire SUMO consensus motif 1 (Δ327-333) and 
SUMO consensus motif 2 (Δ368-374). The indicated constructs were separately over-
expressed in rat primary neuronal cells and immunostained with a, DAPI (blue, nucleus); 
b, neuron specific tubulin (green, cytoskeleton); c, V5 antibody (red, ZBTB20 wild type 
or ZBTB20 SUMO double mutants); d, merged image. The white arrow indicates the 
location of the nucleus of the primary neuronal cell being analyzed. 
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ZBTB20 SUMO mutants do not affect repression activity of ZBTB20 
 
Murine Zbtb20 acts as a transcriptional repressor (Xie et al., 2008, Zhang et al., 
2012, Liu et al., 2013). There is approximately 98% sequence similarity 
between mouse Zbtb20 and human ZBTB20, determined by the ClustalW 
sequence alignment tool. Since human and mouse proteins are very similar, it 
was hypothesized that human ZBTB20 acts as a transcriptional repressor.  
 
Using the Gal4-based transcriptional assay, the transcriptional repression 
activity of ZBTB20 was determined. The Gal4-ZBTB20 fusion vector was 
cotransfected in HEK293H cells with the luciferase reporter construct having 
five Gal4-DNA binding sites (pG5-SV40-Luc) and the Renilla luciferase control 
reporter for normalization. Consistent with the repression activity of mouse 
Zbtb20, wild type human ZBTB20 also acts as transcriptional repressor. As 
shown in Figure 3.8, Gal4-ZBTB20 wild type showed approximately 50% 
reduced relative fold activity as compared to Gal4-empty vector used as control.  
 
Since SUMO modification of transcription repressors facilitates repression (Gill, 
2005; Girdwood et al., 2004), the repression activity of ZBTB20 SUMOylation 
mutants was determined. The Gal4-driven ZBTB20 SUMOylation mutants, 
Gal4-ZBTB20 K330R, Gal4-ZBTB20 K371R or Gal4-ZBTB20 K330R, K371R 
were cotransfected with luciferase and Renilla reporters in HEK293H cells, as 
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described above. All three ZBTB20 SUMO mutants showed repression activity, 
similar to the wild type ZBTB20, shown in Figure 3.8. Thus using the Gal4-
based transcriptional assay, ZBTB20 SUMOylation mutants did not appear to 
affect the repression activity of human ZBTB20 in HEK293H cells.  
 
 
 
Figure 3.8: Transcriptional repression activity of Gal4-driven ZBTB20 wild 
type and SUMO acceptor site mutants 
HEK293H cells were cotransfected with Gal4-ZBTB20 long wild type or ZBTB20 
SUMOylation mutants (Gal4-ZBTB20 K330R, Gal4-ZBTB20 K371R or Gal4-ZBTB20 
K330R, K371R) along with pG5-SV40 luciferase reporter and pRL-TK (Renilla 
luciferase) as internal control. Results are expressed as relative fold luciferase activity 
with respect to the Gal4-empty vector (control) normalized to 1. Error bars represent 
standard deviation from three samples at the same condition. 
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ZBTB20-SUMO1 binding does not affect its stability 
 
SUMOylation has been shown to play an important role in regulating the stability 
of target proteins. To determine the effect of SUMOylation on the stability of 
ZBTB20, a cycloheximide time-course experiment was performed. 
Cycloheximide is an inhibitor of protein biosynthesis in eukaryotes and is used to 
determine the stability of proteins in cell lines. V5-tagged ZBTB20 wild type or 
ZBTB20 SUMOylation mutants (ZBTB20 K330R or ZBTB20 K371R) were 
transfected in HEK293H cells, followed by treatment with and without 
cycloheximide. Protein was isolated both at the start of cycloheximide treatment 
as well as 36 hours post-treatment, with and without cycloheximide. The 
cycloheximide treated V5-tagged ZBTB20 wild type protein did not show any 
significant change in protein expression as compared to untreated cells (Figure 
3.9, lane 4,5). Moreover, there was no significant change in protein expression 
with and without cycloheximide treatment in ZBTB20 SUMOylation mutants 
K330R (Figure 3.9, lane 6,7) and K371R (Figure 3.9, lane 8,9). Thus both 
ZBTB20 wild type and SUMOylation mutants appeared to be equally stable. This 
suggests that SUMOylation likely does not play a role in the stability of ZBTB20.  
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Figure 3.9: Protein stability of wild type and SUMO mutant ZBTB20 
Cycloheximide (CHX) stability assay of HEK293H cells transfected with wild type 
ZBTB20 long isoform (WT) or ZBTB20 SUMOylation mutants (K330R and K371R). 
HEK293H cells were treated with 100 µg/ml cycloheximide (+) or DMSO alone (-) for 36 
hours. Time 0 hour represents protein lysate obtained at the time of initiation of CHX 
treatment. Western blot analysis was performed using anti-V5 antibody (upper panel) 
and with anti-GAPDH (lower panel) as a loading control. 
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ZBTB20 SUMO acceptor lysine mutant, K330R interferes in the 
dimerization of ZBTB20 
 
The BTB/POZ (broad complex, tramtrack, bric-a-brac/pox-virus and zinc finger) 
domain represents a major protein-protein interaction interface for BTB/POZ 
zinc finger transcription factors (Bardwell and Treisman, 1994). Using co-
immunoprecipitation analysis in HEK293H cell lysates (Chapter 2), the homo- 
and heterotypic interaction between human ZBTB20 long and short isoforms 
was determined (Figure 3.10, lanes 1, 2, 3 and 4). The N-terminal region 
containing the BTB domain was found to be critical for the ZBTB20 dimerization 
(Figure 3.10, lower panel, lane 6). To determine whether the ZBTB20 
SUMOylation mutant K330R interferes in ZBTB20 dimerization, V5-tagged 
ZBTB20 long K330R construct was cotransfected with GFP-tagged ZBTB20 
long isoform construct in HEK293H cells. Using V5-antibody for co-
immunoprecipitation followed by Western blot analysis using anti-GFP antibody, 
ZBTB20 K330R-V5 failed to interact with GFP-tagged ZBTB20 long isoform 
(Figure 3.10, lower panel, lane 8), similar to the result of the 
immunoprecipitation reaction between ZBTB20-[BTB]-V5 and GFP-ZBTB20 
long (Figure 3.10, lower panel, lane 6), Thus the co-immunoprecipitation 
analysis in HEK293H cells indicates that the lysine 330 SUMO acceptor residue 
possibly interferes in ZBTB20 dimerization.  
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Figure 3.10: SUMO acceptor site mutant, ZBTB20 K330R prevents 
homodimerization with ZBTB20 long isoform 
Western blot analysis showing HEK293H cell lysates (lane L, input) and co-
immunoprecipitates (Lane IP, immunoprecipitate) co-transfected with the indicated 
GFP-tagged and V5-tagged plasmids and immunoprecipitated using anti-V5 antibody. 
GFP-ZBTB20 long isoform was cotransfected with ZBTB20 long-V5, ZBTB20 short-V5, 
ZBTB20-[-BTB]-V5 or ZBTB20 K330R-V5 in HEK293H cells. Western blot analysis 
using anti-GFP antibody (lower panel) detected GFP-ZBTB20 long isoform (black 
arrow) when pulled down using ZBTB20 long-V5 and ZBTB20 short-V5 plasmids but its 
signal was significantly reduced when pulled down using ZBTB20-[-BTB]-V5 and 
ZBTB20 K330R-V5 plasmids. Ant-V5 antibody (upper pane) confirmed the presence of 
the V5-tagged plasmids in all the lanes. 
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Discussion 
 
In this chapter, the interaction of ZBTB20 with E2 SUMO conjugating enzyme 
UBC9 and SUMO1 has been described. The results described in this study 
provide evidence suggesting SUMOylation of ZBTB20 long isoform at the lysine 
330 residue. Moreover, the effect of ZBTB20 SUMOylation on the various 
functional roles played by ZBTB20 was explored. 
 
Using ZBTB20 long isoform as bait, SUMO-conjugating enzyme UBC9 was 
identified in the human fetal brain-yeast two-hybrid screen performed to 
determine brain expressed ZBTB20-interacting proteins. This interaction was 
verified by co-expressing both ZBTB20 and UBC9 mammalian expression 
constructs in HEK293H cells, followed by co-immunoprecipitation analysis.  
Our co-immunoprecipitation results demonstrated that, ZBTB20 lacking the N-
terminus that includes the BTB domain, failed to interact with the SUMO 
conjugating enzyme UBC9. Thus, the N-terminal region containing the BTB 
domain is critical for the interaction between ZBTB20 and UBC9, consistent with 
its role in protein-protein interactions (Stogios et al., 2005).  
 
Since ZBTB20 long isoform interacts with UBC9 the ZBTB20 protein sequence 
was analyzed for putative SUMO acceptor lysine residues. Using SUMO 
prediction tools seeSUMO (Teng et al., 2012) and SUMOsp (Ren et al., 2009), 
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two well-conserved putative SUMO consensus motifs at the lysine 330 and lysine 
371 residues in human ZBTB20 protein and its orthologues were identified. 
Proteomic analyses by others have shown that at least half of all SUMO target 
proteins contain consensus SUMOylation sites (Matic et al., 2010). The 
interaction of SUMO1 with ZBTB20 in HEK293H protein extracts, suggests 
posttranslational modification of ZBTB20 by SUMO1 in vivo. This result has been 
recently supported by the identification of Sumo1 conjugated murine Zbtb20 in 
mouse brain by large-scale proteomic analysis (Tirard et al., 2012). Co-
immunoprecipitation reaction in HEK293H cells overexpressing HA-tagged 
SUMO1 and V5-tagged ZBTB20 lysine 330 and lysine 371 mutants, indicate that 
lysine 330 is likely the site of SUMO1-conjugation in ZBTB20.  
 
Covalent modification of target proteins by SUMOylation regulates various 
cellular processes (Geiss-Friedlander and Melchior, 2007). SUMOylation 
facilitates nucleocytoplasmic transport and has been shown to alter intracellular 
localization of substrate proteins (Mahajan et al., 1997; Matunis et al., 1996). To 
determine the effect of SUMOylation on nuclear localization of ZBTB20, wild 
type and ZBTB20 SUMOylation mutants were overexpressed in HEK293H cells 
and rat primary neuronal cells. However mutating the ZBTB20 SUMO acceptor 
lysines as well as the SUMO consensus motifs did not alter the intracellular 
localization of ZBTB20. Thus, the nuclear targeting of ZBTB20 does not appear 
to depend on an intact SUMOylation site, indicating that SUMOylation is 
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dispensable for the nuclear localization of ZBTB20. In fact, nuclear localization 
of many proteins were unaffected by SUMOylation (Snow et al., 2010; Wilson 
and Rosas-Acosta, 2005). 
 
In this study, ZBTB20 SUMOylation mutants did not show any effect on the 
stability of ZBTB20 in HEK293H cells. Transiently overexpressing ZBTB20 
followed by cycloheximide treatment and Western blot analysis showed that the 
ZBTB20 wild type and the ZBTB20 SUMOylation mutants have long half-lives. It 
is however possible that these SUMOylation mutants could differentially affect 
the stability of ZBTB20 in other cell types.  
 
SUMOylation could have a range of effects on the activity of transcription factors. 
In most cases, SUMOylation enhanced the repressive activity of transcription 
factors (Kang et al., 2003; Siatecka et al., 2007), while in other cases 
SUMOylation increased transcriptional activation (Yan et al., 2010). Consistent 
with the role of murine Zbtb20 as a transcriptional repressor, human ZBTB20 
also functions as a transcriptional repressor. However, the ZBTB20 SUMOylation 
mutants showed no measurable change in the transcriptional repression activity 
of ZBTB20. Thus SUMOylation does not appear to play a role in the repression 
function of ZBTB20 using the Gal4-based transcriptional assay. Since this assay 
is independent of the DNA binding capability of human ZBTB20, it is still possible 
that the ZBTB20 SUMOylation mutants facilitate the transcriptional repression 
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function of ZBTB20. These SUMOylation mutants could impair the interaction of 
ZBTB20 with other proteins that facilitate repression, interfering in the repression 
function of ZBTB20. More work needs to be done, to elucidate the role of 
SUMOylation on on the repression function of human ZBTB20. 
 
It was determined that ZBTB20 SUMO mutant K330R impairs dimerization of 
wild type ZBTB20 long isoform. Inability to dimerize could prevent formation of 
homodimers and heterodimers as well as disrupt the interaction of ZBTB20 with 
other proteins. Interestingly murine Zbtb20 shows high expression in the 
hippocampal pyramidal neurons, where both Ubc9 and Sumo1 are also highly 
expressed (Watanabe et al., 2008). Moreover the identification of Sumo1 
conjugated Zbtb20 in Sumo1 knock-in mice by Tirad and coworkers (2013) 
shows that Zbtb20 is post-translationally modified by Sumo1 in mouse brain. 
Thus the inability of ZBTB20 to form dimers in the brain could possibly disrupt its 
function in hippocampal neurogenesis, besides other functions performed by 
ZBTB20. Additional studies need to be performed to elucidate the role of 
SUMOylation on the functions performed by ZBTB20. 
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CHAPTER 4 
 
ZBTB20-DEPENDENT TRANSCRIPTION REGULATION OF 
NEURONAL GENES AND ITS ROLE IN AUTISM AND 
INTELLECTUAL DISABILITY 
  
Introduction 
 
Autism spectrum disorders (ASD) and intellectual disability (ID) are 
neurodevelopmental disorders, often co-morbid, with a combined prevalence 
estimated at more than 3% of the general population (Kim et al., 2011). Autism 
spectrum disorders are characterized by impaired language, communication and 
social skills. Intellectual disability is a limitation in intellectual functioning and 
adaptive behavior with an intelligence quotient (IQ) below 70. ID is found in 
approximately 70% of patients with ASD and conversely at least 10% of patients 
with ID have ASD (Oeseburg et al., 2011). 
 
Both ASD and ID are genetically heterogeneous disorders. It is estimated that 
hundreds of loci distributed throughout the genome likely contribute to the 
susceptibility of ASD (State and Sestan, 2012). There is a growing consensus 
that the transcriptional regulation of many neuronal genes rather than a single 
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gene contributes to manifestation of ASD and ID (Ebert and Greenberg, 2013; 
Tsai et al., 2012; West and Greenberg, 2011). 
 
Transcriptome analysis of both autistic and normal brain suggested the role of 
transcriptional and splicing dysfunction as an underlying cause of neuronal 
dysfunction in some patients (Voineagu et al., 2011). Recently several human 
exome studies suggest a prominent role of the genes involved in transcription 
regulation during brain development in patients with ASD (Iossifov et al., 2012; 
Neale et al., 2012; O'Roak et al., 2012; Sanders et al., 2012). Moreover 
transcription factors specific to a particular layer and neuronal subtypes in the 
neocortex were associated with neurodevelopmental disorders (Kwan et al., 
2012). Transcription factors were shown to play an important role in neuronal 
layer identity, connectivity and axonal projections of pyramidal neurons 
(Molyneaux et al., 2007). In a mouse study, neocortical layer-specific 
transcription factors Tbr1, Sox5, Fezf2, Mef2c and Satb2 were found to play a 
pivotal role in determining the molecular mechanisms underlying neuronal layer 
identities and connectivities of neocortical projection neurons. Thus, the 
dysregulation of transcription factors in the brain could lead to the development 
of ASD and ID.  
 
Murine Zbtb20 was shown to be involved in direct repression of neuronal 
transcription factor genes implicated in development of neocortical projection 
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neurons (Nielsen et al. 2013). Using chromatin immunoprecipitation combined 
with high throughput sequencing (ChIP-Seq), it was shown that the Zbtb20 
protein directly binds the transcription factor genes that regulate projection 
neuron development in the neocortex. Nielsen and coworkers (2013) identified 
42 potential transcription factor-encoding genes that were repressed in the CA1-
transformed hippocampal subiculum and retrosplenial cortex of the Zbtb20 
transgenic mice. It was further observed that most of these Zbtb20 regulated 
transcription factor genes were upregulated in the hippocampus of the Zbtb20 
knockout mice (Nielsen et al., 2010; Nielsen et al., 2013; Xie et al., 2010). 
Several of these transcription factor genes were implicated in corticofugal 
projection neuron specification (Fezf2, Tbr1, Sox5), callosal projection neuron 
identity (Satb2) and upper-layer projection neuron development (Cux1, Cux2, 
Mef2c). Thus, substantial evidence exists to support the role of Zbtb20 as a 
transcriptional repressor of the transcription factor-encoding genes involved in 
the neocortical development. 
 
In this study, by using the human brain integrated microarray dataset (Wang et 
al., 2010), the human ZBTB20 gene was found to be coexpressed with neuronal 
transcription factor genes involved in the development of the neocortical layer-
specific projection neurons. Consistent with their role in neurogenesis, these 
genes were found to be associated with the enriched Gene Ontology terms, 
including synapse formation, synaptic transmission and neurological processes. 
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Moreover, we observed that the overexpression of the wild type ZBTB20 in 
human embryonic kidney cells (HEK293H), represses neuronal transcription 
factor genes MEF2C, TBR1 and FEZF2 previously shown to be associated with 
ASD and ID. The results suggest a possible contribution of ZBTB20-dependent 
transcription regulation mechanism in the development of ASD and ID. 
 
Materials and Methods 
 
ZBTB20 co-expression analysis 
 
The genes co-expressed with ZBTB20 were identified to determine its 
physiological functions. The procedure to obtain the list of ZBTB20 co-expressed 
genes is briefly outlined here. A set of 616 brain-derived microarray expression 
profiles from 32 different brain regions (Wang et al., 2010) were used for the co-
expression analysis. Pearson’s correlation coefficient (r) between the probe sets 
was measured and probe sets with |r| ≥0.3 were selected as co-expressed 
genes.  
 
We made a list of the top ZBTB20 co-expressed genes, both positively and 
negatively correlated with the ZBTB20 gene. Both the positively and negatively 
correlated gene sets were subjected to Gene Ontology functional analysis using 
the DAVID (Database for Annotation, Visualization and Integrated Discovery) 
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software tool (Huang et al. 2007). The DAVID software provides a list of 
functional annotation tools to understand the biological functions of large gene 
sets. Using functional annotation terms, including cellular process (CC), 
molecular function (MF) and biological process (BP), the ZBTB20-coexpressed 
gene clusters were generated by DAVID analysis. 
 
Expression constructs  
 
The ZBTB20 open reading frames corresponding to both the short and long 
isoform ZBTB20 proteins were amplified from the Human Fetal Brain 
MATCHMAKER (Clonetech) cDNA library (Rimsky et al., manuscript in 
preparation). Using a pcDNA 3.1 directional TOPO Expression Kit (Invitrogen) 
the ZBTB20 cDNAs were subcloned into a pcDNA3.1D/V5-His-TOPO vector 
which was tagged with V5 epitope. The QuickChange Site-directed Mutagenesis 
Kit (Stratagene) was used to generate the ZBTB20 mutant constructs, P46R in 
the ZBTB20 long isoform and G346V in the ZBTB20 short isoform 
pcDNA3.1D/V5-His-TOPO vector (Rimsky et al., manuscript in preparation). The 
constructs were sequence verified and their expression further confirmed using 
the TNT T7 Quick Coupled Transcription/Translation system (Promega) and 
analyzed by SDS-PAGE.  
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Quantitative reverse transcription PCR (qRT-PCR) and Western blot  
 
Approximately 3 million HEK293H cells were plated in duplicate on 100 mm Poly-
L-lysine coated plates. HEK293H cells were transfected with 13 µg ZBTB20 
expression plasmids using Lipofectamine 2000 Reagent (Invitrogen) according to 
the conditions specified by the manufacturer. Approximately 48 hours post-
transfection, cells were trypsinized, pelleted and washed with cold Phosphate-
buffered saline (PBS, Sigma). Half of the cells were used for RNA extraction and 
the other half used for protein extraction. RNA extraction was performed using 
the GenElute Mammalian Total RNA Miniprep Kit (Sigma). RNA was cleaned 
using Turbo DNA-free kit (Ambion Life Technologies-Invitrogen) followed by 
lithium chloride precipitation solution (Ambion Life Technologies-Invitrogen). 
Quantitative qRT-PCR was performed using iScriptTM One-Step RT-PCR kit with 
SYBR Green and primers as shown in Table 4.1. Primers used for ZBTB20 qRT-
PCR analysis were 5'-ATGTTCGTACACACAGGTGAGAAG-3' (forward primer) 
and 5'-GCTTGTTGCAGATACTACACTGT-3' (reverse primer) to generate a 
product of 136 base pairs. To determine the normalized expression, ΔΔC(t) was 
calculated using POLR2A as reference gene in regression mode and analyzed 
using the Bio-Rad CFX Manager software. The experiments were repeated three 
times and the p value calculated using the Student’s t-test in Excel.  
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Table 4.1: Quantitative RT-PCR primers to measure the endogenous 
expression of neuronal transcription factor genes in HEK293H cells. 
 
Gene Forward primer 
5’-3’ 
Reverse primer 
5’-3’ 
Product 
Size 
(bp) ! ! ! !
SOX5  TTCCCATCAAGCACCTGTT CTTCAGCCAGAGTTAGCACA 121 
TBR1  CGTGTCATAATTATCCCGAAATCC CAGACGTTCACTTTCCCTGAG 123 
TLE4  TCCTCATTGGAAACGTCAACC ACAGAAACTCCGCAGACTAC 130 
ZFPM2  ATGGCCTTCGTAGTTGTACAC TGGTTGCTGGATGTGACTTG 101 
CUX1 TCACCTCTTCATAGTCAGCCT CAGCCAGATCTCACAGCTTG 101 
CUX2  GTCAGACCCAGGATGCTTTC GACACGTACTCCATCACCAA 92 
FEZF2 GTCAGCTTGTGGTTCTTGTAGT ACGCTCAACACGCATATCC 107 
SATB2 Hs00392652_m1  
(Probe based assay)  
! 109 
FOXP2 TGCCATTGTCTTCCATACTGT AGCACTTCCTGTCCAATCG 104 
MEF2C TGTTGGTGCTGTTGAAGATGA AGATTACGAGGATTATGGATGAACG 138 
RORB TGCAAACTCCACCACGTAT GCAGACCCACACCTATGAAG 115 
Reference ! ! !
POLR2A  TTGTGCAGGACACACTCACA CAGGAGGTTCATCACTTCACC 83 
*Annealing temperature used for all primers was 60 ºC. 
 
Protein extraction and Western blot  
 
Protein lysis was performed in the RIPA lysis buffer [150 mM NaCl;  
1% NP-40; 0.5% Sodium Deoxycholate; 0.1% SDS and 50 mM Tris (pH 8.0)] and 
the protease inhibitor cocktail (Sigma). The cells were vortexed, incubated in ice 
for 30 minutes, sonicated and finally centrifuged to obtain the protein 
supernatant. The protein was quantified using the Pierce BSA protein assay 
(Thermo Scientific) according to the conditions specified by the manufacturer. 
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The quantified protein lysate were run on a SDS-PAGE gel. Western blot 
analysis was performed using the following antibodies to detect endogenous 
ZBTB20 and the overexpressed ZBTB20 constructs in HEK293H cell lysates: 
rabbit anti-ZBTB20 (Aviva Systems Biology) at 1:1000 dilution in 5% milk and 2% 
Bovine serum albumin (BSA; Sigma) in Tris Buffered Saline with Tween 20 
(TBST) overnight at 4°C and mouse anti-V5 (Invitrogen) at 1:5000 dilution in 5% 
milk and 2% BSA in TBST.  
 
Results 
  
ZBTB20 co-expresses with neuronal transcription factor (TF) genes and 
genes implicated in neurodevelopment 
 
The expression of the human ZBTB20 gene isoforms was examined in a cDNA 
panel of human fetal tissues (Clonetech). Both the ZBTB20 gene isoforms show 
increased expression in the human fetal brain and kidney (Rimsky et al., 
manuscript in preparation). Expression of human ZBTB20 was identified 
specifically in the human fetal hippocampus (Nielsen et al., 2013). Not much is 
known about the mechanisms underlying the human ZBTB20 expression and the 
genes that it potentially regulates. On the other hand, expression of murine 
Zbtb20 in the brain was extensively studied. The mouse Zbtb20 gene was 
expressed in neurons of the hippocampus, granule cells in the cerebellum as well 
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as in differentiated glial cells. Both Zbtb20 isoforms showed overlapping 
expression in the brain (Mitchelmore et al., 2002; Nielsen et al., 2007). Recently, 
the Zbtb20-regulated target genes were identified in the murine hippocampus 
(Nielsen et al., 2013) using ChIP-Seq experiments.  
 
To determine the physiological role of ZBTB20, the genes coexpressed with the 
human ZBTB20 gene in the brain microarray expression dataset (Wang et al., 
2010) were identified. To determine the genes repressed by human ZBTB20 in 
brain, the list of genes negatively correlated with ZBTB20 was analyzed using the 
DAVID software tool (Huang da et al., 2007). The genes encoding transcription 
factors were largely negatively correlated with ZBTB20 in the coexpressed gene 
list. Further functional analysis revealed that the top negatively correlated genes 
were enriched with the Gene Ontology terms, including synapse, synapse part, 
postsynaptic membrane, cell junction, and synaptic transmission functions (Table 
4.2). These results are consistent with a recent study (Nielsen et al., 2013), 
which used chromatin immunoprecipitation (ChIP) combined with high throughput 
sequencing to show that Zbtb20 directly binds and represses 42 transcription 
factor genes involved in neurogenesis, axonogenesis, dendritogenesis and 
neuronal circuit formation. The list of murine Zbtb20 repressed transcription 
factor genes were analyzed. As expected majority of these transcription factor 
genes, showed negative correlation in expression with the ZBTB20 gene. As 
shown in Table 4.3, MEF2C, CUTL2, SATB2, TBR1, FOXP2 and RORB showed 
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the highest negative correlation with the ZBTB20 gene expression. Previous 
studies have shown that several of these transcription factor genes are 
repressed in the hippocampus of Zbtb20 (short isoform) overexpressing 
transgenic mice (Nielsen et al., 2007; Nielsen et al., 2013) while derepressed in 
the hippocampus of Zbtb20 null mice (Xie et al., 2010). Thus, ZBTB20 represses 
the transcription factor genes involved in neurodevelopment. 
 
ZBTB20-mediated repression of transcription factor genes associated with 
ASD and ID 
 
To evaluate ZBTB20-mediated repression of human transcription factor genes, 
both the long and short isoforms of ZBTB20 protein were individually 
overexpressed in HEK293H cells (Figure 4.1). The ZBTB20 protein was 
overexpressed by transiently transfecting V5-tagged ZBTB20 short or long 
isoform mammalian expression constructs in HEK293H cells. The expression of 
both ZBTB20 RNA (Figure 4.1A) as well as ZBTB20 protein (Figure 4.1B) was 
observed to be approximately 1000 fold higher in both ZBTB20 long and short 
isoform overexpressed HEK293H cells as compared to the untransfected 
HEK293H cells. 
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Table 4.2: Functional annotation clustering of top negatively correlated 
ZBTB20 co-expressed genes (complete list not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annotation Cluster 1 Enrichment 
Score: 11.79 
Gene 
count 
P_Value Benjamini 
GOTERM_CC_FAT Synapse 80 2.40E-15 6.30E-13 
GOTERM_CC_FAT synapse part 61 8.90E-14 1.50E-11 
GOTERM_CC_FAT postsynaptic 
membrane 
38 1.50E-10 2.00E-08 
GOTERM_CC_FAT cell junction 87 2.50E-09 2.60E-07 
Annotation Cluster 2 Enrichment 
Score: 7.81 
   
GOTERM_BP_FAT synaptic 
transmission 
64 8.50E-13 2.70E-09 
GOTERM_BP_FAT transmission 
of nerve 
impulse 
67 5.30E-11 8.50E-08 
GOTERM_BP_FAT cell-cell 
signaling 
89 2.30E-08 6.80E-06 
GOTERM_BP_FAT neurological 
system 
process 
114 5.50E-02 6.20E-01 
!
143 
Table 4.3:  Transcription factor genes negatively correlated with the 
ZBTB20 gene expression.  
 
Correlation 
Coefficient 
 
Affymetrix 
Probe 
 
Gene – Description 
 222357_at ZBTB20 - zinc finger and BTB domain containing 20  
-0.51 207968_s_at MEF2C - myocyte enhancer factor 2C  
-0.46 213920_at CUTL2 - cut-like 2 (Drosophila)  
-0.46 213435_at SATB2 - SATB homeobox 2 
-0.46 220025_at TBR1 - T-box, brain, 1  
-0.44 1552902_a_at FOXP2 - forkhead box P2 (GB: NM_148898,  
-0.41 242385_at RORB - RAR-related orphan receptor B  
-0.37 217707_x_at SMARCA2 - SWI/SNF related, matrix associated,  
actin dependent regulator of chromatin, subfamily a, 
member 2  
-0.32 221086_s_at FEZF2 - FEZ family zinc finger 2  
-0.31 226048_at MAPK8 - mitogen-activated protein kinase 8  
-0.27 208889_s_at NCOR2 - nuclear receptor co-repressor 2  
-0.25 215591_at SATB2 - SATB homeobox 2  
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Figure 4.1: Overexpression of ZBTB20 long or short isoform in HEK293H 
cells 
Endogenous and exogenous A. ZBTB20 RNA expression measured using qRT-PCR 
and B. ZBTB20 protein expression observed by Western blot analysis. HEK293H cells 
overexpressing V5-tagged ZBTB20 long or short isoform plasmids (as indicated above) 
and un-transfected HEK293H cells were used for ZBTB20 RNA and protein expression 
analysis. ZBTB20 expression was normalized to POLR2A and represented as fold 
change of expression relative to un-transfected cells. Anti-ZBTB20 antibody was used 
for Western blot analysis.  
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Next, the endogenous expression levels of transcription factor genes previously 
found to be regulated by Zbtb20 protein in murine brain were analyzed. Nielsen 
and coworkers (2013) showed that murine Zbtb20 binds to neuronal transcription 
factor genes that regulate neuronal subtype specification in the developing 
neocortex. Moreover, Zbtb20 repressed these neocortical transcription factor 
genes in the CA1 transformed subicular and retrosplenial cortex brain regions in 
the Zbtb20 transgenic mice.  
 
HEK293H cells overexpressing either the long or short isoform of ZBTB20 were 
analyzed for the endogenous expression of human transcription factor genes, 
TBR1, MEF2C, FEZF2, SOX5, ZFPM2, RORB, TLE4, FOXP2, and CUX1 by 
quantitative reverse-transcription PCR. The overexpression of the ZBTB20 long 
isoform resulted in a significant reduction in the expression of MEF2C and TBR1 
while overexpression of the ZBTB20 short isoform resulted in reduced 
expression of the FEZF2 gene (Figure 4.2). No significant change in expression 
was observed for the endogenous expression of SOX5, ZFPM2, RORB, TLE4, 
FOXP2, and CUX1 in HEK293H cells overexpressed with either of the two 
isoforms of ZBTB20 protein as shown in Figure 4.2.  
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Figure 4.2: Endogenous RNA expression levels of transcription factor 
genes in HEK293H cells overexpressing human ZBTB20 long or short 
isoform 
Endogenous RNA levels of transcription factor genes previously regulated by murine 
Zbtb20 and associated with neurodevelopmental disorders were quantified by qRT-PCR 
in HEK293H cells overexpressing human ZBTB20 long isoform (Long WT) and ZBTB20 
short isoform (Short WT) isoforms. Transcript levels were normalized to POLR2A and 
represented as fold change of expression relative to untransfected HEK293H cells. *P< 
0.05; n.s., not significant.  
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   Table 4.4: Potential roles and contribution of ZBTB20 and ZBTB20-   
   regulated neuronal transcription factors to neurodevelopmental disorders 
Transcription 
factors 
Physiological roles References 
ZBTB20 Deletions and mutations in ASD and 
ASD/ID; 
Affects dendritic spine morphology and 
dendritic arborization; Binds and 
represses genes involved in neuronal 
subtype specification in mice developing 
isocortex. 
 Molin et al., 2012; Nielsen 
et al., 2013; Wiśniowiecka-
Kowalnik et al., 2013) and 
Rimsky et al., manuscript in 
preparation. 
SOX5  Deletions and mutations in ID, speech 
delay, variable behavioral abnormalities 
Lamb et al., 2012; Lee et 
al., 2013; Schanze et al., 
2013) and Rimsky et al., 
manuscript in preparation. 
TBR1 Mutations in patients with  autisms; 
Mutations and deletions in patients with 
ID, developmental delay, ASD, speech 
disorder, seizures, brain malformations, 
hypotonia, and behavioral abnormalities; 
Regulates expression of AUTS2, a gene 
implicated in ID and autism; Binds XLID 
encoding protein CASK1 
  
Bedogni et al., 2010; 
O’Roak et al., 2012; Traylor 
et al., 2012; Wang et al., 
2004 
MEF2C Deletions and mutations in patients with 
ID; Associated with ASD, epilepsy and 
behavioral abnormalities; Negative 
regulator of synapse number and 
function 
Barbosa et al., 2008; 
Bienvenu et al., 2013; Le 
Meur et al., 2010; Li et al., 
2008; Novara et al., 2010; 
Nowakowska et al., 2010; 
Paciorkowski et al., 2013; 
Zweier et al., 2010 
FEZF2 Directly repressed by TBR1, implicated 
in autism; Regulates pyramidal 
morphology, dendritic patterning, and 
spine number; An SNP near 5’ proximal 
region of FEZF2 is associated with ASD; 
Chen et al., 2005; Han et 
al., 2011; Kwan et al., 2008; 
Leone et al., 2008; 
Molyneaux et al., 2007; 
Wang et al., 2009 
CUX1/ 
CUX2 
Regulate dendritic branching, spine 
morphology, and synapses of the upper 
layer neurons of the cortex; Cux1 
regulates ENGRAILED2 autism 
spectrum disorder-associated haplotype 
function 
 Choi et al., 2012; Cubelos 
et al., 2010; Li et al., 2010 
SATB2 Disrupted and deleted in patients with ID 
microdeletion syndrome; Disrupted in a 
patient with ASD, developmental 
dyspraxia; Role in dendritic arborization 
in mice cerebral cortex 
Marshall et al., 2008; 
Rosenfeld et al., 2009; 
Talkowski et al., 2012; 
Zhang et al., 2012 
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Transcription 
factors 
Physiological roles References 
RORB Deleted in patients with ID, speech 
delay, epilepsy and characteristic facial 
features; 9q21.13 microdeletion 
syndrome; Genetic association with  
bipolar disorder; Genetic association with 
verbal intelligence 
Boudry-Labis et al., 2013; 
Ersland et al., 2012; 
McGrath et al., 2009; 
Partonen, 2012 
FOXP2 Mutations in patients with speech and 
language  impairment; regulates gene 
networks implicated in neurite outgrowth 
in the developing brain 
Lai et al., 2001; MacDermot 
et al., 2005; Vernes et al., 
2011 
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Transcription factor genes MEF2C, TBR1 and FEZF2 are repressed by 
ZBTB20 overexpression but unaffected by ASD and ID associated ZBTB20 
variants 
 
In the previous section, overexpression of ZBTB20 long isoform resulted in the 
reduced expression of transcription factor genes MEF2C and TBR1, while 
overexpression of the ZBTB20 short isoform resulted in reduced expression of 
transcription factor gene FEZF2 in HEK293H cells. 
 
The effect of overexpression of the ASD associated ZBTB20 long isoform variant 
P46R and ASD and ID associated ZBTB20 short isoform variant G346V on the 
negatively correlated TF genes was measured in HEK293H cells. Both the 
ZBTB20 isoforms and the corresponding mutants were overexpressed in 
HEK293H cells and their protein expression was observed by Western blot 
analysis using anti-V5 antibody (Figure 4.3). Overexpression of ZBTB20 long 
isoform mutant P46R in HEK293H cells failed to repress the expression of 
transcription factor genes MEF2C (Figure 4.4A) and TBR1 (Figure 4.4B). Also, 
the ZBTB20 short isoform mutant G346V showed no change in the expression of 
the transcription factor gene FEZF2 repressed by the overexpression of wild type 
ZBTB20 short isoform as shown in Figure 4.4C. Thus the ASD and or ID 
associated ZBTB20 variants showed expression similar to the wild type, 
indicating lack of repressor activities. 
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Figure 4.3: ASD and ID associated ZBTB20 variants in the long and short 
isoforms of ZBTB20 
A. ASD and ID associated ZBTB20 protein variants, P46R in long isoform and G346V in 
short isoform (G419V in long isoform) are shown. The BTB domain (BTB) and five zinc 
fingers (ZnFs) are present in both ZBTB20 short and long isoforms. A region specific to 
the long isoform that extends from amino acid 1 to 73 amino acids is indicated (orange 
box). B. ZBTB20 protein expression, in HEK293H cells overexpressing V5-tagged 
ZBTB20 long WT, ZBTB20 long P46R, ZBTB20 short WT and ZBTB20 short G346V. 
Anti-V5 antibody was used to detect long (black arrow) and short isoform (blue arrow) 
wild type and mutant ZBTB20 in Western blot analysis. 
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A 
 
B 
 
C 
 
Figure 4.4: Effect of overexpression of ZBTB20 wild type and mutants on 
endogenous RNA levels of the indicated transcription factor genes 
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Figure 4.4: Effect of overexpression of ZBTB20 wild type and mutants on 
endogenous RNA levels of the indicated transcription factor genes 
Endogenous RNA levels of A. MEF2C; B.TBR1 were quantified by quantitative reverse-
transcription PCR in HEK293H cells overexpressing human ZBTB20 long isoform 
(ZBTB20 Long WT) and ZBTB20 P46R mutant. Endogenous RNA levels of C. FEZF2 
were also quantified by quantitative reverse-transcription PCR in HEK293H cells 
overexpressing human ZBTB20 short isoform (ZBTB20 WT) and mutant ZBTB20 
G346V.Transcript levels were normalized to POLR2A and represented as fold change of 
expression relative to untransfected HEK293H cells. *P< 0.05; n.s., not significant. 
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Figure 4.5: Schematic representation of ZBTB20-dependent transcription 
repression of neuronal transcription factor genes and their association 
with neurodevelopmental disorders 
ZBTB20 acts as a master-regulator of transcription through repressing several neuronal 
transcription factors, including TBR1, SOX5, FOXP2, CUX1/CUX2, RORB, ZFPM2, 
FEZF2, and SATB2 (lines in black; Nielsen et al., 2013; Present study). These 
transcription factors bind and repress additional transcription factors (dashed lines; See 
Table 4.4 for details and references) and regulate target genes (lines in grey; 
References in Table 4.4). 
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Discussion 
 
In this chapter, the co-expression of human ZBTB20 gene with several neuronal 
transcription factor genes that are associated with neurodevelopmental disorders 
including autism spectrum disorders, intellectual disability, and speech delay 
(Table 4.4, Figure 4.5) was determined. The ZBTB20 gene expression in brain 
was found to be largely negatively correlated with transcription factor genes 
enriched in Gene Ontology terms including synapse, postsynaptic membrane 
and synaptic transmission. In this study, overexpression of human ZBTB20 gene 
in HEK293H cells resulted in the repression of neuronal transcription factor 
genes TBR1, MEF2C, and FEZF2, previously found to be associated with 
neurodevelopmental disorders (Table 4.4).  
 
Various studies in mouse brain have shown that murine Zbtb20 is expressed 
during early differentiation of the CA1 and CA3 pyramidal neurons of the 
Ammon’s horn and granule cells of the dentate gyrus in the developing 
hippocampus (Mitchelmore et al., 2002). Zbtb20 expression was strictly confined 
to the developing hippocampal neurons in the mouse brain. On the other hand, 
the neighboring neocortical and transitional areas adjacent to the hippocampus 
are conspicuous by the absence of Zbtb20 expression. Further, Zbtb20 plays an 
important role in determining the hippocampal CA1 pyramidal neuron identity 
(Nielsen et al., 2007; Rosenthal et al., 2012; Xie et al., 2010) in the mouse brain. 
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Zbtb20 represses neuronal subtype-specific neocortical transcription factor 
genes in the mice hippocampus (Nielsen et al., 2010; Nielsen et al., 2013). Using 
chromatin immunoprecipitation (ChIP) combined with multi-parallel sequencing 
(Chip-Seq) Nielsen and coworkers (2013) have shown that murine Zbtb20 binds 
neuronal transcription factor genes, including Cux1, Cux2, Fezf2, Foxp2, Mef2c, 
Rorb, Satb2, Sox5, Tbr1, Tle4 and Zfpm2. These transcription factor genes 
control neuronal subtype specification in the developing neocortex. They further 
showed that Zbtb20 represses these genes during CA1 pyramidal neuron 
development in Zbtb20 transgenic mice. Thus murine Zbtb20 suppresses 
neocortical cell fate transitions and ensures commitment to hippocampal CA1 
pyramidal neuron fate by repressing neocortical transcription factor genes in the 
developing projection neurons. These findings suggest the potential role of 
human ZBTB20-dependent transcription regulation in the developing brain.  
 
Recent research on neocortical development has emphasized the role of 
transcription factors in neuronal identity, neuronal migration and neuronal wiring 
(Kwan et al., 2012). There are different subclasses of projection neurons in the 
neocortical deep layers. Specification of projection neurons in deep layer of 
neocortex requires a network of transcription factors. These transcription factors 
repress other transcription factor genes of alternative deep-layer fates. Since 
autism spectrum disorders develop very early in life and impair the functioning of 
the neocortex, any sort of abnormal neocortical circuit miswiring has been 
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hypothesized to result in autism spectrum disorders (Kwan et al., 2012). Tbr1, 
Sox5, Fezf2 and Satb2 are some of the neocortical layer specific transcription 
factors that are found to be critical for neuronal identity, connectivity and axonal 
projections and are implicated in autism spectrum disorders as shown in Table 
4.4. Thus the disruption of these neuronal transcription factor genes could result 
in neurodevelopmental disorders including autism spectrum disorders and 
intellectual disability. 
 
Using quantitative RT-PCR to measure the endogenous expression of 
transcription factor genes in HEK293H cells overexpressed with ZBTB20 long 
isoform, the expression of T-box containing transcription factor gene, TBR1 was 
found to be repressed. TBR1 is involved in laminar identity and axonal migration 
in early brain cortical development and has been implicated in autism (O'Roak et 
al., 2012). It regulates the expression of AUTS2, a gene implicated in ASD 
(Bedogni et al., 2010). TBR1 has also been observed to bind an X-linked 
intellectual disability (XLID) gene CASK (Wang et al., 2004). Patients with 
deletions in the 2q24 region encompassing the TBR1 gene have been found to 
be associated with severe speech and language difficulties, autism-like 
behavioral problems and moderate to severe ID (Traylor et al., 2012). Moreover 
many studies have also identified larger deletions encompassing the TBR1 gene 
(Krepischi et al., 2010; Magri et al., 2011; Palumbo et al., 2012; Takatsuki et al., 
2010;Traylor et al., 2012). The common phenotypic features shared by all these 
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TBR1 gene deletion cases were absent or delayed speech and language as well 
as ID. Single nucleotide variations of TBR1 have been reported in sporadic ASD 
cases with or without ID (O’Roak et al., 2012; O'Roak et al., 2012).  
 
Besides TBR1, the expression of MEF2C was also significantly repressed in 
HEK293H cells overexpressing ZBTB20 long isoform. Various studies have 
shown the involvement of MEF2C in neurogenesis, neuronal migration and 
differentiation and its association with ASD and ID (Table 4.4). Deletions in 
MEF2C have been reported in patients with ID as well as ASD (Novara et al., 
2010; Nowakowska et al., 2010; Zweier et al., 2010). Moreover, MEF2C gene 
deletion associated with ID, autistic features, epilepsy and abnormal hand 
movements is being increasingly recognized as a neurodevelopmental syndrome 
(Paciorkowski et al., 2013). MEF2C has also been shown to be involved in 
regulation of synapse number and function (Flavell et al., 2006). Expression of 
Mef2C has also been shown to be upregulated in mice deficient in MECP2 gene, 
implicated in Rett syndrome (Li et al., 2008). 
 
Another neuronal transcription factor gene FEZF2, implicated in autism spectrum 
disorder (Sanders et al., 2012; Wang et al., 2009) and neuronal development 
(Chen et al., 2005) is down-regulated by overexpression of the short isoform 
ZBTB20 in HEK293H cells. FEZF2 is directly repressed by TBR1 (Chen et al., 
2005) and has been shown to regulate pyramidal neuron morphology, dendritic 
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patterning and dendritic spine number (Han et al., 2011; Kwan et al., 2008; 
Leone et al., 2008; Molyneaux et al., 2007).  
  
The genetic alterations in the ZBTB20 gene along with the transcription factor 
genes regulated by the ZBTB20 protein has been shown to play an important 
role in ASD and ID.  Since ZBTB20 regulates the expression of several of these 
neuronal transcription factor genes, it could potentially play the role of a master 
regulator as shown in Figure 4.5. It is hypothesized that the coordinated 
expression of the various neuronal genes is critical for homeostasis and a slight 
imbalance of any of these well-coordinated transcription factor genes could result 
in neurodevelopmental disorders (Ramocki and Zoghbi, 2008; Toro et al., 2010).  
 
The expression of the ZBTB20 gene is largely negatively correlated with genes 
implicated in transcription regulation. Many neuronal transcription factor genes 
enriched in roles associated with neurodevelopment are negatively correlated 
with the expression of ZBTB20 gene in the ZBTB20 co-expressed gene list. Two 
of these neuronal transcription factor genes MEF2C and TBR1 previously shown 
to be associated with ASD and ID were found to be repressed in HEK293H cells 
overexpressed with the ZBTB20 long isoform. Moreover, overexpression of the 
ZBTB20 short isoform in HEK293H cells resulted in reduced FEZF2 expression. 
It is intriguing that many neuronal transcription factor genes found to repressed in 
Zbtb20 transgenic mice during ectopic CA1 pyramidal neuron development were 
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not repressed in the ZBTB20 overexpressed HEK293H cells. One possible 
reason to explain these findings could be that various transcription factors are 
expressed in a neuronal subtype-specific as well as neocortical layer-specific 
manner, thus it might be difficult to reproduce the effect of ZBTB20-mediateded 
repression in mammalian cell lines like HEK293H. In the future, neuronal cell 
lines could be used to study the effect of ZBTB20-dependent regulation of the 
neuronal transcription factor genes associated with ASD and ID. 
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CHAPTER 5 
 
ZBTB20 siRNA KNOCKDOWN  
 
Introduction 
 
The ZBTB20 gene is located at chromosomal position 3q13.2 (Zhang et al., 
2001) and consists of 10 exons spanning 880 kb of genomic DNA. The ZBTB20 
protein contains the BTB/POZ (Broad Complex, Tramtrack, Bric a Brac/ 
Poxvirus and zinc finger) domain at the N-terminal and five C2H2 Kruppel-type-
zinc fingers at the C-terminal.  
 
The ZBTB20 gene was identified as a strong candidate gene for autism 
spectrum disorders (ASD) and intellectual disability (ID). One chromosomal 
copy of the ZBTB20 gene was found to be physically disrupted by a t(3;12) 
translocation in a patient with autistic features and developmental delay. Two 
missense ZBTB20 mutations unique to ASD and or ASD/ID and a de novo 
intragenic deletion encompassing the ZBTB20 gene have been identified in a 
patient with borderline intelligence, impulsivity and attention deficit.  Recently 
several cases with microdeletions in the region of 3q13.31 have been identified 
in microdeletion syndrome patients encompassing the ZBTB20 gene. Variable 
clinical features such as attention deficit, autistic features, intellectual disability 
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and developmental delay have been reported and provide further evidence of a 
likely involvement of ZBTB20 gene in the clinical spectrum of 
neurodevelopmental disorders such as ASD and ID (Rimsky et al., manuscript 
in preparation; Molin et al., 2012; Vuillaume et al., 2013; Wisniowiecka-
Kowalnik et al., 2013).  
 
Murine Zbtb20 has been well studied using both overexpression and knockout 
experiments to understand its physiological functions. Transgenic mice with 
overexpression of the Zbtb20 gene in hippocampal subiculum as well as non-
hippocampal areas show hippocampus-like corticoneurogenesis and behavioral 
abnormalities (Nielsen et al., 2007). Furthermore, Zbtb20 knockout mice 
provide strong evidence of a role for the Zbtb20 protein in hippocampal 
development, especially in determination of CA1 field identity of the 
hippocampus. Absence of Zbtb20 resulted in transformation of the CA1 field to 
a neocortex-like structure and reduction in size of the hippocampus (Xie et al., 
2010). Nielsen and coworkers (2013) demonstrated that the Zbtb20 directly 
binds and represses several neocortical layer-specific transcription factors 
genes including Myocyte-specific enhancer factor 2C (Mef2c) and T-box brain 1 
(Tbr1). Murine Zbtb20- regulated neuronal transcription factor genes have been 
shown to be associated with neurodevelopmental disorders, including autism 
spectrum disorder and intellectual disability  (Bienvenu et al., 2013; 
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Nowakowska et al., 2010; O'Roak et al., 2012; Traylor et al., 2012; Zweier and 
Rauch, 2012).   
 
Since murine Zbtb20 regulates the expression levels of many 
neurodevelopmental disorder-associated transcription factor genes, we 
hypothesized that human ZBTB20 may also function as a regulator of these 
transcription factor genes. A slight imbalance in the expression of any of the 
neuronal transcription factor genes associated with neurodevelopmental 
disorders, including ASD and ID, could result in the clinical presentation of the 
phenotype. Since little is known about human ZBTB20 transcription factor- 
regulated target genes, we used small interfering RNA (siRNA) to knockdown 
the ZBTB20 gene expression in two human cells lines to study the effect on 
ZBTB20-regulated target genes. 
 
Material and Methods 
 
HEK293H cell culture  
 
HEK293H (Human Embryonic Kidney cell line 293H) were cultured using 
standard protocols. HEK293H cells were maintained in cell media consisting of 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma) supplemented with 10% 
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fetal bovine serum (FBS; Atlanta Biologicals), 1% penicillin/streptomycin 
(Sigma) and 1% L-glutamine (Sigma) and maintained at 37°C and 5% CO2.  
 
Undifferentiated ReNcell VM, a human neural progenitor cell culture  
 
ReNcell VM (Millipore) is neural progenitor cell line derived from human ventral 
mesencephalon brain tissue. ReNcell VM cells were plated on 60 mm dishes 
that were pre-coated with laminin (Sigma) in DME/F12 (Millipore) for at least 4 
hours at 37°C. The undifferentiated ReNcell VM cells were maintained in the 
ReNcell maintenance media (Millipore) supplemented with growth factors 
including fibroblast growth factor (FGF, Millipore) and epidermal growth factor 
(EGF Millipore) added to the growth media at a concentration of 20 ng/ml each. 
Cells were detached from the plate using Accutase (Millipore), subcultured 
every two days and maintained at 37°C and 5% CO2.  
 
HEK293H siRNA transfection 
 
Approximately a half million HEK293H cells were plated on laminin pre-coated 
60 mm dishes in HEK293H cell media (described above) without the antibiotics 
penicillin/streptomycin for 18-20 hours at 37°C and 5% CO2. ZBTB20 siRNA 
(ON-TARGETplus ZBTB20 siRNA; Thermo Scientific) or control siRNA (ON-
TARGETplus Non-targeting Pool; Thermo Scientific) suspended in antibiotic-
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free media were mixed with the transfection reagent (DharmaFECT; Thermo 
Scientific). The siRNA and the transfection reagent suspended in antibiotic-free 
media were incubated for 20 minutes at room temperature and transfected in 
the HEK293H cells. The transfected HEK293H cells were harvested at 24 hours 
for RNA analysis and 48 hours for protein analysis. The siRNA sequences in 
the ON-TARGETplus Human ZBTB20 siRNA SMARTpool are: 
GCAAUUCCGUGCUCGAGAC, CGACAAGAGCGUCCUACAA, 
ACACAGGAGUGAGGGCAUA and GCAUGUGUCUGACGGAUAA. 
 
ReNcell VM siRNA transfection 
 
Approximately a half million ReNcell VM cells were plated on laminin pre-coated 
60mm dishes in DME/F12 antibiotic-fee media and incubated at 37°C and 5% 
CO2 overnight. The old media was then replaced with fresh DME/F12 antibiotic- 
free media. ZBTB20 siRNA (ON-TARGETplus ZBTB20 siRNA; Thermo 
Scientific) or control siRNA (ON-TARGETplus Non-targeting Pool; Thermo 
Scientific) was transfected along with the DharmaFECT (Thermo Scientific) 
transfection reagent according to the manufacture’s protocol.  
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RNA extraction and qRT-PCR 
 
The ReNcell VM cells were detached from the plates for RNA extraction using 
Accutase (Millipore), while HEK293H cells were detached using Trypsin + 
EDTA (Sigma), 24 hours post-transfection. Cells were suspended in RNA lysis 
buffer (Sigma) and 2-Mercaptoethanol (BME; Sigma) and subjected to RNA 
extraction using the GenElute Mammalian Total RNA Miniprep Kit (Sigma) 
protocol. The RNA was cleaned using Turbo DNA-free DNase (Ambion Life 
Technologies-Invitrogen) kit followed by precipitation using the lithium chloride 
precipitation solution (Ambion Life Technologies-Invitrogen).  
 
Quantitative RT-PCR was performed using iScript One-Step RT-PCR kit with 
SYBR Green (BioRad) and the following ZBTB20 forward and reverse primers 
were used to generate a 136 base pair product:  
5'-ATGTTCGTACACACAGGTGAGAAG-3' and  
5'-GCTTGTTGCAGATACTACACTGT-3’. Normalized expression ΔΔC(t) was 
determined using POLR2A as a reference gene in regression mode and plotted 
using Bio-Rad CFX manager software. The experiments were repeated three 
times and the p value between untransfected and siRNA transfected cells was 
calculated using the Student’s t-test.  
 
 
!
181 
Protein lysates and Western blot analysis  
 
Protein was extracted from HEK293H cells and VM cells using the NP40 lysis 
method. Cells were washed with ice cold phosphate buffered saline and 
incubated in 1%NP-40 lysis buffer (1%NP-40; 150 mM NaCl; 50 mM Tris pH 
8.0) and protease inhibitor cocktail (Sigma) for approximately 10 minutes on ice 
to dissociate the cells. The cells were sonicated 3 times at 10% amplitude for 2 
seconds each followed by centrifugation. The protein concentration was 
measured using coomassie (Bradford) protein assay reagent. The protein lysate 
was boiled for 3-5 minutes in SDS sample buffer. The protein was separated on 
a SDS-PAGE gel, transferred on the membrane and then probed with rabbit 
anti-ZBTB20 antibody (Aviva Systems Biology) at 1:1000 dilution in 5% milk 
and 2% Bovine serum albumin (BSA; Sigma) in Tris Buffered Saline with Tween 
20 (TBST) overnight at 4°C and mouse anti-GAPDH (Santa Cruz) in 2% BSA 
TBST at 1:5000 dilution for 1 hour at room temperature, used as loading 
control.  
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Results 
 
ZBTB20 gene knockdown in HEK293H and ReNcell VM cells 
 
To determine the effect of reduced expression of the ZBTB20 gene on other 
genes in the human cell, we performed ZBTB20 knockdown in two human cell 
lines: HEK293H, a human embryonic kidney cell line and ReNcell VM, a human 
neural progenitor cell line. The goal of this study is to look for the effect of 
reduced expression of the ZBTB20 gene on other ZBTB20-regulated target 
genes including ASD and ID implicated neuronal transcription factor genes. 
 
The ZBTB20 gene is expressed both in HEK293H cells, as well as in ReNcell VM 
cells. A pool of 4 human ZBTB20-specific siRNA was used to knockdown the 
ZBTB20 gene expression. Using a gradient of ZBTB20 siRNA concentrations, 
transfection reagent as well as cell densities, the level of ZBTB20 knockdown in 
both HEK293H and ReNcell VM cells was measured.   
 
Using 25 nM of ZBTB20 siRNA in 0.5X 106 HEK293H cells, approximately 50% 
knockdown was achieved at the RNA level as shown in Figure 5.1A. The same 
concentration of non-targeting siRNA (negative control) did not show ZBTB20 
knockdown, similar to untreated cells, indicating specificity of ZBTB20 
knockdown. Approximately 50% ZBTB20 knockdown was observed only in 
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HEK293H cells transfected with the ZBTB20 siRNAs, while ZBTB20 expression 
remained unchanged in both untransfected cells as well as in cells treated with 
the non-targeting negative control. 
 
To investigate the effect of ZBTB20 knockdown at the protein level, both treated 
and untreated HEK293H cell lysates were prepared to detect the level of ZBTB20 
protein by Western blot analysis. We used a ZBTB20-specific antibody to detect 
the protein in total protein lysates in ZBTB20 siRNA-treated, non-targeting 
control-treated and untreated HEK293H cells. The level of ZBTB20 protein in 
ZBTB20 siRNA-treated HEK293H cells was reduced approximately 50% as 
compared to non-targeting control-treated protein lysate or untreated HEK293H 
cells (Figure 5.1B).  
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A 
 
B 
 
Figure 5.1: ZBTB20 knockdown in HEK293H cells using ZBTB20 siRNA  
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Figure 5.1: ZBTB20 knockdown in HEK293H cells using ZBTB20 siRNA  
A. Quantitative RT-PCR analysis of ZBTB20 transcript levels and B. Western blot 
analysis of ZBTB20 protein in ZBTB20 siRNA pool-treated, non-targeting control- treated 
and untreated HEK293H cells. ZBTB20 transcript levels were normalized to POLR2A 
and represented as fold change of expression relative to untreated HEK293H cells. *P< 
0.05. Western blot analysis was performed using anti-ZBTB20 antibody. Black arrow 
indicates endogenous ZBTB20 and blue arrow indicates GAPDH. 
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Since ZBTB20 is highly expressed in the hippocampal primordium of developing 
mouse brain  (Mitchelmore et al., 2002) as well as in the human fetal 
hippocampus  (Nielsen et al., 2013, Rimsky et al., Manuscript in preparation) we 
chose ReNcell VM, a human neural progenitor cell line for our knockdown 
experiments. We transfected 0.5X 106 ReNcell VM cells plated on a 60 mm dish 
with 75 nM of ZBTB20 siRNA pool using DharmaFECT transfection reagent. 
Approximately 50% knockdown was achieved in the ZBTB20 siRNA treated 
ReNcell VM cells, while both control siRNA-treated and untreated ReNcell VM 
cells did not show reduced ZBTB20 RNA expression (Figure 5.2) 
 
 
 
Figure 5.2: ZBTB20 knockdown in ReNcell VM cells using ZBTB20 siRNA 
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Figure 5.2: ZBTB20 knockdown in ReNcell VM cells using ZBTB20 siRNA 
Quantitative RT-PCR analysis of ZBTB20 transcript levels in ZBTB20 siRNA 
SMARTpool treated, non-targeting control treated and untreated ReNcell VM. Transcript 
levels were normalized to POLR2A and represented as a fold change of expression 
relative to untreated ReNcell VM.  
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Discussion 
 
In this study, we knocked down the expression of the ZBTB20 gene in two 
human cell lines, HEK293H and undifferentiated ReNcell VM cells. RNA 
isolated from the ZBTB20 gene knockdown human cell lines will be useful in the 
identification of genes both upregulated and down-regulated as a result of 
ZBTB20 gene knockdown.  
 
ZBTB20 siRNA SMARTpool used to knockdown ZBTB20 gene expression 
consists of four 19-nucleotide double-stranded RNA. The RNAi induced 
silencing complex (RISC) in the cell guides the siRNAs to the target RNA 
sequence, in this case the last two coding exons of the ZBTB20 gene. The 
argonaute protein, which is part of the RISC complex, unwinds the double 
stranded siRNA, such that only the antisense strand remains bound to the 
argonaute protein (Dykxhoorn et al., 2003). Finally, the antisense strand 
together with the RISC complex directs the degradation of the complementary 
ZBTB20 mRNA.  
 
The ZBTB20 mRNA expression level was knocked down by approximately 
50%, measured by quantitative RT-PCR. Studies done in Zbtb20 knockout mice 
have shown that the murine Zbtb20 gene is essential for survival and postnatal 
growth. Zbtb20 knockout mice show postnatal lethality and do not survive for 
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more than 12 weeks of age (Sutherland et al., 2009). Moreover, ZBTB20 RNA 
expression is reduced by approximately 50% in patients having a ZBTB20 gene 
deletion. Thus the siRNA mediated 50% ZBTB20 gene knockdown that has 
been achieved in this study is similar to the ZBTB20 RNA expression level in 
ZBTB20 deletion patients.  
 
We will perform a human transcriptome analysis using the HEK293H and 
ReNcell VM ZBTB20 knockdown RNA samples. We will use the GeneChip® 
Human Transcriptome Array 2.0 (Affymetrix) to identify the genes differentially 
expressed in ZBTB20 knockdown samples with respect to untransfected cells. 
The GeneChip Human Transcriptome Array 2.0 is a commercial microarray, 
which is designed to provide human transcriptome analysis at high-resolution, 
even for less abundantly expressed genes. Identifying the ZBTB20-regulated 
target genes in human cells would help us understand the complex interplay 
between these genes leading to the onset of neurodevelopmental disorders 
including ASD and ID. This information would also complement the results from 
the ZBTB20 overexpression analysis done in human embryonic kidney cells. 
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CONCLUSIONS 
 
The ZBTB20 gene has been found to be associated with autism spectrum 
disorders (ASD) and intellectual disability (ID) in our laboratory. It has also been 
identified as a candidate gene for developmental delay and other clinical features 
observed in the 3q13.31 microdeletion and microduplication syndrome. The 
mechanisms underlying the functional role of the BTB (Broad Complex, 
Tramtrack, Bric-a-Brac) -zinc finger containing transcription factor, ZBTB20 in 
ASD and ID are still not fully understood. While the role of murine Zbtb20 is 
better characterized, the functional properties and pathways underlying human 
ZBTB20 are just beginning to be unraveled. The purpose of this study was to 
functionally characterize the human ZBTB20 protein to elucidate its contribution 
to ASD and ID. The work presented here has identified potential molecular links 
by which the ZBTB20 protein functions in mammalian cells and has also provided 
insight into molecular mechanisms and functional pathways underlying ASD and 
ID.  
 
The first chapter provides a detailed review about the ZBTB20 protein, its 
domains and their known functions. The physiological functions of the murine 
Zbtb20 transcription factor protein, the murine Zbtb20-regulated target genes and 
its associated biological processes have been described. Analyzing the 
functional roles of Zbtb20 in mice has enabled a better understanding about the 
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possible roles of the human ZBTB20 protein. Further, the post-translational 
modification SUMOylation and its biological functions have been described. 
Finally, the possible roles of SUMOylation on neuronal proteins were described, 
which should help understand the possible effects of SUMOylation on ZBTB20. 
 
The second chapter describes the functional characterization of the human 
ZBTB20 in mammalian cell lines. In mammalian cells, ZBTB20 localizes primarily 
in the nucleus and the long- and short- isoform ZBTB20 proteins form 
homodimers and heterodimers. Moreover, the N-terminal region of ZBTB20 
containing the BTB domain is found to be critical for its dimerization. Using a 
yeast two-hybrid screen with ZBTB20 long isoform as bait, eight novel proteins 
that interact with ZBTB20 were identified. Further functional analysis of the 
ZBTB20-interacting proteins in mammalian cells could help define the molecular 
mechanisms underlying the physiological functions of ZBTB20 in the brain.  
 
The third chapter describes the SUMOylation of ZBTB20 and the functional 
effects of ZBTB20-SUMO1 conjugation. The interaction of ZBTB20 with E2 
SUMO conjugating enzyme UBC9 and SUMO1 in human embryonic kidney cells 
has been studied. Moreover, the effects of ZBTB20 SUMOylation on its stability, 
intracellular localization, repression function and dimerization have been 
examined. The interaction of ZBTB20 with SUMO1 and UBC9 has opened new 
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areas of research into the role of ZBTB20 SUMOylation on neuron development 
in brain and other ZBTB20-regulated biological processes. 
 
The fourth chapter describes the ZBTB20-dependent transcription regulation of 
coexpressed neuronal transcription factor genes MEF2C, TBR1 and FEZF2, 
previously found to be associated with ASD and ID. The expression of neuronal 
transcription factor genes MEF2C, TBR1 and FEZF2 was significantly reduced in 
HEK293H cells overexpressing either the long or the short isoform ZBTB20 
protein. Future studies of various neuronal transcription factor genes regulated 
by human ZBTB20 protein would provide new insight into the development of 
ASD and ID.  
 
Finally, the fifth chapter describes the siRNA-mediated knockdown of ZBTB20 in 
two human cell lines, HEK293H cells and the ReNcell VM cells, a human neural 
progenitor cell line. The ZBTB20 knockdown RNA sample will be used to analyze 
the expression of genes regulated by ZBTB20. 
 
The ZBTB20 functional studies presented here have helped to further the 
understanding of the functional role of human ZBTB20 and SUMO1 modified 
ZBTB20 in mammalian cells. ZBTB20 K330 residue, which is part of the 
SUMOylation consensus sequence, was shown to play a role in ZBTB20 
homodimerization. It is possible that SUMOylation facilitates protein-protein 
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interaction of ZBTB20. In fact, loss of ZBTB20 SUMOylation could affect the 
interaction of ZBTB20 with zinc finger proteins ZMYM5 and ZMYM2, which are 
part of the transcriptional corepressor complex. Proteins containing the BTB 
domain frequently interact with components of the transcriptional corepressor 
complex. These transcriptional corepressor proteins associate with histone 
deacetylase complex and other corepressor proteins that are involved in 
chromatin modification. In this work, ZBTB20 coexpression analysis has revealed 
significant negative correlation with NCOR2 (nuclear receptor co-repressor-2), 
which is a component of the histone deacetylase complex. ZBTB20 expression is 
also negatively correlated with SWI/SNF, components of the chromatin-
remodeling complex as well as other neuronal transcription factor proteins. Thus 
ZBTB20 could potentially interact with co-repressors and other proteins to cause 
repression of gene expression by modifying chromatin, consistent with the role of 
BTB containing proteins. 
 
ZBTB20 interacting proteins and ZBTB20 regulated target genes will be further 
investigated using RNA isolated from ZBTB20 gene knockdown in HEK293H and 
ReNcell VM cells. Identification of ZBTB20-regulated genes would help in 
delineating the molecular mechanisms and pathways underlying ZBTB20 
function. Moreover, studies showing ZBTB20-dependent transcription regulation 
could provide further evidence supporting the role of ZBTB20 in 
neurodevelopmental disorders.  
